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Purpose 
 Dose conformality and robustness are equally important in Intensity-Modulated 
Proton Therapy (IMPT). Despite the important role of beam orientation on both dosimetry 
and robustness, an automated, robust beam orientation optimization algorithm has not 
been incorporated due to the problem complexity and paramount computational challenge. 
In this dissertation, we propose a novel IMPT framework that integrates robust beam 
orientation optimization (BOO) and robust fluence map optimization (FMO) in a unified 
framework. 
 iii 
Methods 
 The unified framework is formulated to include a dose fidelity term, a 
heterogeneity-weighted group sparsity term, and a sensitivity regularization term. The 
dose fidelity term encourages less physical dose deviation from ideal distribution. The 
L2,1/2-norm group sparsity is used to reduce the number of active beams from the initial 
1162 evenly distributed non-coplanar candidate beams, to between 2 and 4. A 
heterogeneity index, which evaluates the lateral tissue heterogeneity of a beam, is used to 
weigh the group sparsity term. With this index, beams more resilient to setup uncertainties 
are encouraged. There is a symbiotic relationship between the heterogeneity index and the 
sensitivity regularization; the integrated optimization framework further improves beam 
robustness against both range and setup uncertainties. This Sensitivity regularization and 
Heterogeneity weighting based BOO and FMO framework (SHBOO-FMO) was tested on two 
skull-base tumor (SBT) patients and two bilateral head-and-neck (H&N) patients. The 
conventional CTV-based optimized plans (Conv) with SHBOO-FMO beams (SHBOO-Conv) 
and manual beams (MAN-Conv) were compared to investigate the beam robustness of the 
proposed method. The dosimetry and robustness of SHBOO-FMO plan were compared 
against the manual beam plan with CTV-based voxel-wise worst-case scenario approach 
(MAN-WC). 
Results 
 With SHBOO-FMO method, the beams with superior range robustness over manual 
beams were selected while the setup robustness was maintained or improved. On average, 
the lowest [D95%, V95%, V100%] of CTV were increased from [93.8%, 91.0%, 70.6%] in 
 iv 
MAN-Conv plans, to [98.6%, 98.6%, 96.1%] in SHBOO-Conv plans with range uncertainties. 
With setup uncertainties, the average lowest [D98%, D95%, V95%, V100%] of CTV were 
increased from [92.0%, 94.8%, 94.3%, 78.9%] in MAN-Conv plans, to [93.5%, 96.6%, 
97.0%, 91.9%] in SHBOO-Conv plans. Compared with the MAN-WC plans, the final SHBOO-
FMO plans achieved comparable plan robustness and better OAR sparing, with an average 
reduction of [Dmean, Dmax] of [6.3, 6.6] GyRBE for the SBT cases and [1.9, 5.1] GyRBE for 
the H&N cases from the MAN-WC plans.  
Conclusions 
 A novel robust optimization method was developed for IMPT. It integrates robust 
BOO and robust FMO into a unified framework, and the resulting optimization problem can 
be solved efficiently. Compared with the current clinical practice, where beam angles are 
manually selected and fluence map is optimized by worst-case method, the planning 
efficiency is improved, and it generates plans with superior dosimetry and good 
robustness.  
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 1 
1 INTRODUCTION 
1.1 Intensity-Modulated Proton Therapy  
 Since the discovery and first medical application of X-rays in 18951, radiation 
therapy has been one of the primary treatments for cancer. The ultimate goal of radiation 
therapy is to deliver a sufficient dose to eradicate cancerous tissue, while minimizing the 
irradiation to healthy tissue. Many developments and improvements have been made to 
reach this goal. Among them, utilizing the unique dose deposition characteristic of proton 
particles has drawn massive attention. As shown in Figure 1-1, compared with the photon, 
proton beam has low entrance-dose, a sharp rise near the end of its range, which is called 
Bragg peak, and negligible exit-dose. The finite range and the characteristic Bragg peak 
make proton a promising radiotherapy modality to spare healthy tissue while delivering a 
conformal dose to the target. 
 Since 1946 when the concept was first brought up by Wilson2, proton therapy has 
been gradually translated into clinical treatment. The protons generated by an accelerator, 
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either a cyclotron or a synchrotron, forms a narrow pencil beam. In order to cover the 
entire treatment field, the narrow pencil beam needs to be scattered by a foil or scanned by 
magnets, referred to as passive scattering and active scanning3, respectively (Figure 1-2).  
Even though passive scattering was the mainstream due to its simplicity, the freedom of 
modulation is limited, and the dose conformality fails to outperform than the commonly 
used Intensity-Modulated X-ray Therapy (referred to as IMXT). The recent decade sees 
rapid development and increasing adoption of pencil beam scanning (PBS) technique4 in 
proton therapy. With PBS, the energy and intensity of the Bragg peaks of well-defined 
narrow pencil beams can be modulated in 3D space to generate a sophisticated dose 
distribution for tumor coverage and normal tissue sparing5,6. This technique is called 
Intensity-Modulated Proton Therapy (IMPT). The pencil beam scanning is also called spot-
scanning, and the narrow pencil beam is referred to as scanning-spot, or spot, as well. 
 
Figure 1-1: Depth-dose curve of photon beam and monoenergetic proton beam. 
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Figure 1-2: The difference of passive scattering and active scanning. The narrow proton 
beam from a cyclotron or synchrotron is either scattered by a foil or scanned by magnets to 
cover the treatment field. Reprinted from “Intensity-Modulated Radiation Therapy, 
Protons, and the Risk of Second Cancers” by E. Hall and D. Phil, Int J Radiat Oncol Biol Phys, 
2006 ,65(1):1-7. Copyright 2006 by Elsevier Inc. 3 
 There are several variations of intensity modulation, including 2D modulation, 
distal edge tracking, 2.5D modulation, and 3D modulation5.  Among them, 3D modulation 
places the Bragg peaks throughout the target volume in 3 dimensions and optimizes the 
intensity of each individual pencil beam, therefore fully takes advantage of the freedom of 
Bragg peaks localizations. 3D IMPT can be further divided into two categories, single-field 
uniform dose (SFUD) and multi-field optimization (MFO)5. In SFUD, each radiation field is 
optimized independently to achieve a uniform dose distribution. In MFO, all fields are 
optimized simultaneously. Therefore each field generates a highly heterogeneous dose, but 
the combination from all fields achieves a highly conformal dose. MFO-IMPT utilizing all 
available degrees of freedom has the greatest versatility for normal organ sparing. This 
dissertation focuses on MFO-IMPT, which will be simply termed IMPT in the following 
sections. 
 4 
1.2 Uncertainties in IMPT 
 Due to the sharp drop-off of proton Bragg peak, IMPT is very sensitive to 
uncertainties occurring during planning and delivery, including setup errors, patient 
anatomy changes, and range uncertainties7–11. The setup uncertainties are from the 
misalignment between patient anatomy and proton beams as well as the shifting of internal 
density heterogeneity8. The range uncertainties originate from various sources, such as CT 
(Computed Tomography) image artifacts, uncertainties in CT numbers, and the conversion 
from CT numbers to stopping powers. Patient anatomy change and tumor shrinkage will 
also lead to different proton range than expected. The existence of these uncertainties can 
make the actual dose distribution substantially differ from what is indicated in the 
treatment plan. Different from X-ray treatment planning, the perturbation of dose 
distribution in IMPT not only exists in the proximal and distal edge of the target volume but 
also within it, introducing significant cold or hot spots. 
 Multi-field optimized IMPT is even more susceptible to positioning errors or range 
uncertainties due to the high dose heterogeneity in a single field. In MFO, the dose in an 
individual beam is not homogeneous and only covers a partial volume of the target, with 
the rest usually compensated by the dose from other fields. Range uncertainties can 
possibly lead to overshooting (protons shoot deeper than expected) or undershooting 
(protons shoot shallower than expected) of two compensating beams, leaving cold or hot 
spots in the target.  
 If uncertainties are unaccounted for, the effectiveness of IMPT from Bragg peak 
and 3D modulation may be greatly diminished by its high sensitivity.  Therefore, dose 
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conformality and plan robustness are two equally critical factors to consider in IMPT 
treatment planning. 
1.3 Beam Orientation Optimization 
 A typical treatment planning process of IMPT involves three steps: first, a number 
of proton beams are manually selected by the planner. For complicated cases, multiple tries 
are needed to decide the number and orientations of beams; second, proton pencil beam 
dose calculation is performed for these beams; finally, inverse planning is carried out to 
obtain the intensity map and final dose distribution6. The intensity map of the scanning-
spots is also referred to as the fluence map. The inverse planning process to obtain the 
fluence map is called fluence map optimization (FMO).  
 Different from X-ray therapy where equiangular or arc beams are often acceptable, 
the proton beam orientations are typically asymmetric, and need to be more carefully 
considered for factors such as the water-equivalent thickness to the target, nearby OAR 
sparing, heterogeneity of tissues in the beam path, and setup robustness etc12–14. Because 
of the unique proton beam physics, the need to further reduce body dose, the limited beam 
time, and to relieve the patient-specific QA efforts, 2~4 proton fields are typically utilized 
in an IMPT session6,15. The smaller number of beams makes the selection of proton beam 
angle particularly important. In the current clinical practice of manual beam selection, 
planners’ experience and skill can heavily influence the final treatment plan quality.  For 
complicated patient cases, tedious trial-and-error attempts may be needed to find better 
beam configurations. Yet, human operators cannot effectively search the enormous 
coplanar and non-coplanar beam space, resulting in inconsistent planning results. Beam 
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orientation optimization (BOO) using a computational model is therefore essential for 
improving IMPT.  
1.4 Biological Effectiveness 
 Aside from robustness, the biological effect is another prominent issue to consider 
for IMPT. While conventional radiation treatment is prescribed based on the physical 
absorbed dose, it is insufficient for proton. The difference in radiation interactions makes 
the energy deposition pattern differ between photons and protons; thus, the same 
absorbed dose can lead to various biological outcomes. The concept of relative biological 
effectiveness (RBE) was developed to account for the biological effect when comparing 
different modalities under the same physical dose. RBE is defined as the ratio of the 
physical doses to reach the same endpoint X when comparing a reference radiation source 
and proton.  
𝑅𝐵𝐸(EndpointX) =
𝐷𝑜𝑠𝑒𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒(EndpointX)
𝐷𝑜𝑠𝑒𝑝𝑟𝑜𝑡𝑜𝑛(EndpointX)
 
Equation 1-1    
 As recommended by the International Commission on Radiation Units and 
Measurements (ICRU)16, the doses in proton therapy are prescribed as the product of RBE 
and absorbed dose, with the unit of GyRBE. 
 In the current clinical application, proton therapy is regarded to be 10% more 
effective than high-energy photons, represented by a constant RBE of 1.117–19. However, the 
constant 1.1 value is an average of in vivo measurements performed around 1970s20–23. 
Multiple pieces of evidence have shown that actual RBE depends on multiple factors like 
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physical dose, tissue radiobiological properties (𝛼  and 𝛽  value), LET (linear energy 
transfer), endpoint, and et al17,24–26. In vitro study suggests that, given dose, cell type and 
biological endpoint, the RBE may increase from values between 1.0 and 1.1 in the entrance 
region to values around 1.3 at the Bragg peak and 1.6 in the falloff region27. Therefore, even 
though an ideal physical dose distribution is guaranteed, it is possible to induce higher 
normal tissue complication probabilities when RBE in normal tissue is underestimated. In 
addition, with the pencil beam scanning technique replacing passive scattering to be the 
mainstream delivery modality, the biological doses potentially differ from the previous 
observation on passive scattering28,29, warranting further investigation in the universal use 
of RBE=1.1. 
 There have been concerns that using the generic RBE value in proton therapy can 
lead to underdosage in the target or underestimation of the normal tissue toxicities. 
Therefore, it is essential to incorporate the biological dose into clinical treatment planning 
to achieve a higher therapeutic ratio. Moreover, the ability to optimize biological 
effectiveness depends on patient geometry and beam arrangement30. For example, if an 
OAR abuts the target in the distal edge of a proton beam, it is difficult to reduce the 
biological dose in this OAR without compromising physical dose coverage. In clinical 
practice, a planner can avoid some of the undesirable beam orientations based on 
experience31–34, but evaluating all beam angles for their dosimetry, robustness, and the 
biological effect is a large computational task unsuited for human operators. A beam 
orientation optimization algorithm for both physical and biological dose optimization is 
essential for IMPT. 
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1.5 Overview 
Prior to presenting the beam orientation optimization method integrating dosimetry 
and robustness of IMPT, separate investigations performed related to IMPT BOO problems 
will first be discussed. 
Chapter 2 describes the unified framework integrating BOO and FMO in IMPT based 
on the group sparsity regularization, to select beams and generate plans with superior 
dosimetry. It is the foundation for the rest studies in this thesis. It is a version of a 
manuscript titled “Integrated beam orientation and scanning-spot optimization in Intensity 
Modulated Proton Therapy for brain and unilateral head and neck tumors” published in 
Medical Physics35. 
In Chapter 3, works utilizing the group sparsity for different aspects of proton 
therapy will be discussed. First is a work using group sparsity to select variant beams in 
different treatment fractions to further improve the dosimetry of IMPT plans. The 
manuscript titled “Fraction-Variant Beam Orientation Optimization for Intensity-
Modulated Proton Therapy” has been submitted to Medical Physics. The second section is a 
study integrating biological effectiveness into BOO of IMPT, to achieve superior physical 
and biological dose distribution. The manuscript titled “Biological effectiveness-integrated 
beam orientation optimization for Intensity-Modulated Proton Therapy” has been 
submitted to Medical Physics. The third section describes an optimization method for 
proton arc therapy based on group sparsity, to improve dosimetry and delivery efficiency 
from the IMPT. It is a version of the manuscript titled “A novel energy layer optimization 
framework for spot-scanning proton arc therapy” published in Medical Physics36. 
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Chapter 4 describes the robust optimization method with sensitivity regularization 
and combines it with group sparsity to achieve robust integrated BOO and FMO framework 
in IMPT. The first section is a version of the manuscript “Robust optimization for Intensity-
Modulated Proton Therapy with soft spot sensitivity regularization” published in Medical 
Physics37, detailing the formulation of sensitivity regularization. The second section 
integrates sensitivity regularization and group sparsity for the ultimate goal of robust IMPT 
BOO, which is a version of the manuscript “Robust beam orientation optimization for 
Intensity-Modulated Proton Therapy” published in Medical Physics38. 
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2 INTEGRATING BEAM 
ORIENTATION AND FLUENCE 
MAP OPTIMIZATION IN 
IMPT BASED ON GROUP 
SPARSITY REGULARIZATION 
2.1 Introduction 
 Because of the small beam number in IMPT plans (2~4 proton fields), each beam 
heavily influences the final quality. The importance of beam orientation was highlighted in 
several studies12–14. However, due to the vast search space, it is essentially impossible for a 
human operator to test all combinations and find the optimal set of beams. Especially non-
coplanar space is commonly used in proton therapy because of the modern robotic patient 
positioning device typically installed in a proton treatment room. Therefore, there arises a 
need for beam orientation optimization (BOO) for IMPT. 
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 For IMXT, BOO is viewed as a combinatorial problem, which by its nature is 
mathematically intractable for realistic BOO problems. The challenge is greater with the 
additional depth dimension in IMPT optimization. While methods for IMXT BOO have been 
developed using heuristic and stochastic algorithms to overcome the mathematical 
challenge9–15, the BOO problem is rarely touched in IMPT. In a previous study by Cao et 
al.46, the coplanar BOO problem was treated as a combinatorial problem. To reduce the 
problem size, starting from a set of initial beams, a local search was performed to identify 
beams that improve dosimetric quality and robustness. This method is clearly limited in its 
ability to perfrom a global search in a large solution space, like the 4𝜋 steradians. 
 In this study, we present a novel framework to efficiently integrate BOO and FMO 
that allows a global search in all feasible beams. The problem is formulated to include a 
dose fidelity term and a group sparsity regularization to control the number of active 
beams. Group sparsity, also known as structured sparsity, was originally used in optimizing 
X-ray beam orientations and showed the potential of reducing the number of beams yet 
maintaining dense beamlets47.  
 In this work, different regularization and dose fidelity terms are introduced as well 
as a solver that is capable of handling a larger problem than the original IMXT BOO 
problem owing to the additional depth dimension. 
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2.2 Methods 
 The group sparsity based integrated BOO and scanning-spot optimization problem 
is formulated under two different dose fidelity terms, with either convex or nonconvex 
group sparsity term. The details are described as follows. 
2.2.1 Problem formulation 
 The simultaneous beam orientation and scanning-spot intensity optimization 
problem is formulated under the following general framework: 
minimize
𝑥
   Γ(𝐴𝒙) +∑𝛼𝑏‖𝒙𝑏‖2
𝑝
𝑏∈ℬ
, 
subject to    𝒙 ≥ 0, 
Equation 2-1    
where the optimization variable 𝒙 is a vector of the intensities of all scanning-spots, which 
is the fluence map. 𝐴 is the dose-calculation matrix that transforms the spot intensities 𝒙 to 
dose. A single column of matrix 𝐴 contains the vectorized doses delivered to the voxels in 
the patient from one unit intensity spot; and 𝐴 includes columns of all the candidate spots 
from all candidate beams. ℬ is the set including all candidate beams, 𝒙𝑏 is a vector of spot 
intensities for the candidate beam 𝑏 (so 𝒙 is the concatenation of the vectors 𝒙𝑏), and 𝛼𝑏 is 
the regularization parameter for beam 𝑏. Γ(𝐴𝒙) is a dose fidelity term, to penalize dose 
deviation from prescriptions. ∑ 𝛼𝑏‖𝒙𝑏‖2
𝑝
𝑏∈𝐵   is the group sparsity term to control the 
number of active beams to between 2 and 4. The L2,𝑝-norm (0 < 𝑝 ≤ 1) encourages most 
candidate beams to be zero, resulting in a small number of beams being selected. A 
common choice for the exponent for the group sparsity term is  𝑝 = 1, which makes the 
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objective function convex. However, in the BOO problem, the adjacent block columns of the 
dose-calculation matrix (corresponding to adjacent candidate beams) can be correlated in 
homogeneous areas. Subsequently, the group restricted isometry property may not be well 
satisfied and the L2,1-norm may lead to a degenerate solution, i.e. aggregated beams. To 
avoid degeneracy, the nonconvex group sparsity with 𝑝 = 1/2 is also explored in this study. 
We choose the weighting parameter 𝛼𝑏 on the individual beam 𝑏 to be 
𝛼𝑏 = 𝑐 (
‖𝐴𝒯
𝑏  ?⃗? ‖
2
𝑛𝑏
)
𝑝/2
, 
Equation 2-2    
where 𝐴𝒯
𝑏  is the dose-calculation matrix of planning target volume (PTV) for beam 𝑏, 𝑛𝑏 is 
the number of candidate spots in beam 𝑏, and 𝑐 is a regularization parameter. The term 
‖𝐴PTV
𝑏  ?⃗? ‖
2
 in the numerator is used to ensure that beams penetrating different depths in 
the patient are unbiasedly weighted. Without this term, the group sparsity has a tendency 
towards only selecting beams passing through less tissue. The denominator 𝑛𝑏 prevents 
the group sparsity penalty from having a bias against the beams with more spots. By this 
weighting method, we are able to tune a single parameter 𝑐 to control the number of active 
beams in the solution to Equation 2-1. 
 In this work, PTV is designated to be the target volume for dose optimization. 
Although the concept of PTV originally from X-ray therapy is not exactly applicable in IMPT 
to maintain tumor coverage48,49, without losing generality, the term PTV here is used to 
indicate the target volume without the additional implication of plan robustness. 
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2.2.2  Dose fidelity 
 The function Γ can take different forms based on the dosimetric goals and whether 
a compatible solver exists. Two different choices of Γ are implemented and compared in 
this work.  
 The first is the quadratic loss function, which is a common choice for dose fidelity. 
The overall cost is written as: 
Γ(𝐴𝒙)  = ∑𝜔𝑗
𝑗∈𝒯
‖𝐴𝑗𝒙 − 𝑝𝑗‖2
2
+∑𝜔𝑗
𝑗∈𝒪
‖(𝐴𝑗𝒙 −𝑚𝑗)+‖2
2
, 
Equation 2-3    
where 𝒯 is the structure set of the target volumes, with 𝑝𝑗  being the prescription dose to 𝑗th 
target, and 𝒪  is the dose-limiting structure set which includes the OARs, with 𝑚𝑗  being the 
prescribed maximal allowed dose to the 𝑗th structure. 𝐴𝑗  is the dose calculation matrix block for 
structure 𝑗. The dose-limiting penalty terms utilize the one-sided quadratic function‖𝑧+‖2
2, 
where 𝑧+ = max(𝑧, 0). This component-wise maximum allows us to consider only the 
voxels with doses larger than 𝑚𝑗  in the 𝑗th OAR. 𝑚𝑗  can also be set to 0 to penalize any 
nonzero dose in an OAR. The weights 𝜔𝑗  are the structure-specific weighting parameters to 
emphasize the different importance of different structures.  
 The quadratic penalty is mathematically desirable for being convex and 
differentiable. It heavily penalizes the dose volumes that exceed the constraint. However, in 
radiation therapy, more controls on the dose volume behavior are often desirable. For 
serial organs, such as the spinal cord, hot spots need to be avoided. However, for parallel 
structures, such as the parotid glands, the mean dose can be more important than the 
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maximum dose. Therefore, the second type of function Γ we use is a linear combination of 
structure mean dose and maximum dose penalty, which is referred as the linearized 
equivalent uniform dose (LEUD)50 cost function in this work. The LEUD penalty function is 
formulated as: 
Γ(𝐴𝒙)  =∑
𝜔𝑗
√𝑁𝑗𝑗∈𝒯
‖𝐴𝑗𝒙 − 𝑝𝑗‖2 +∑𝜔𝑗 (𝛾𝑗mean(𝐴𝑗𝒙) + (1 − 𝛾𝑗)max(𝐴𝑗𝒙))
𝑗∈𝒪
+ 𝐼≤𝑞(𝐴𝒙), 
Equation 2-4    
where 𝑁𝑗  is the number of voxels in 𝑗th target, and the weighting factor 𝛾𝑗 ∈ [0,1] balances 
the mean dose and maximum dose for different organs. The penalty on the target is a voxel-
normalized L2-norm. The L2-norm is chosen because it has better coverage than the L1-
norm (which is mean(|𝐴𝑗𝒙 − 𝑝𝑗|)), and is consistent with the OAR cost with regard to the 
order (the quadratic term is in the order of 2, while the mean dose is linear). Because the 
L1-norm on OARs (mean dose) is not as sensitive to outliers, it allows for hot spots in 
parallel OARs. Therefore, in order to eliminate any dose higher than the upper bound dose 
𝑞, an upper bound constraint 𝐼≤𝑞(𝐴𝒙) is added to the objective function. 𝐼≤𝑞(𝑧) is defined 
as: 
𝑰≤𝒒(𝒛) = {
𝟎          𝐢𝐟    𝒛 ≤ 𝒒,
  ∞         𝐨𝐭𝐡𝐞𝐫𝐰𝐢𝐬𝐞.
 
Equation 2-5    
2.2.3 Evaluations 
 Four cases, which included three unilateral head and neck (H&N) patients and one 
skull base chordoma (CHDM) patient with simultaneous-integrated boost (SIB), were 
evaluated in this study. The candidate beams included 1162 non-coplanar beams that were 
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evenly distributed across the 4𝜋 steradians with 6° separation. Geometrically undesired 
beams and beams of infeasible energies, such as those directed through the feet to the head, were 
manually excluded from the candidate set, resulting in about 700 to 800 candidate beams for 
each patient. For each candidate beam, the doses of all scanning-spots covering the PTV and 
a 2.5mm margin were calculated using matRad51,52, a MATLAB-based 3D treatment 
planning toolkit. The dose calculation resolution was 2.5 mm with a cut-off of 5 × 10−5 of 
the maximal dose. The prescriptions, PTVs, and number of scanning-spots are shown in 
Table 2-1. The magnitude of the optimization problem can be estimated based on the 
product of the spot number per beam and the total number of candidate beams. The 
average number of beamlets per beam needed in IMXT for the same patient is also given in 
Table 2-1 as a comparison of the BOO problem size in IMPT and in IMXT. The IMXT 
multileaf collimator resolution is 5 mm. 
Case 
Prescription 
Dose 
(GyRBE) 
PTV Volume 
(cc) 
Average Spots 
Number per 
Beam 
Average IMXT 
Beamlets Number 
per Beam 
H&N #1 40 23.76 906 85 
H&N #2 40 32.29 1109 103 
H&N #3 66 33.64 1589 111 
CHDM 
PTV6300 63 86.07 
3166 241 
PTV7400 74 26.42 
Table 2-1: Prescription doses, PTV volumes, and average spots number per beam of each 
tested patient. 
 A greedy BOO approach, column generation53,54,  was also applied for each patient, 
as a comparison for our group sparsity method.. The dose fidelity term used in the column 
generation method is LEUD cost. 
 The BOO plans were evaluated against plans with manually selected beams. The 
manual beam orientations were selected to avoid OARs as much as possible. In total, 7 
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plans were generated for each patient: three plans with quadratic dose fidelity: manual 
plan (Quad-MAN), L2,1/2-group sparsity (Quad-L2,1/2-GS) and L2,1-group sparsity(Quad-
L2,1-GS); and four plans with LEUD dose fidelity: manual plan (LEUD-MAN), L2,1/2-group 
sparsity(LEUD-L2,1/2-GS), and L2,1-group sparsity (LEUD-L2,1-GS), and column 
generation (LEUD-CG). All H&N plans were normalized so that 100% of the prescription 
dose covers 95% of the PTV volume. The CHDM plan with a simultaneous boost volume 
was normalized to have 100% of the 63Gy prescription dose covering 95% of the PTV6300 
volume.  
 For evaluation, PTV homogeneity, D95, D98, D99, maximum dose and mean dose 
were evaluated. PTV homogeneity is defined as D95/D5. The maximum dose is defined as 
the dose to 2% of the structure volume, D2, following the recommendation by IRCU-8355. 
The mean and maximum doses for OARs were also evaluated.  
2.3 Results 
 The matRad-based dose calculation for all candidate beams using an i7 6-core CPU 
and Matlab parallel computing toolbox took 30 min to 1 h depending on the size of the 
tumor. The dose matrix size ranged from 20 MB to 70 MB per beam based on target size. 
The group sparsity based BOO process took 2 - 7 minutes and 3 - 20 minutes for the 
quadratic and LEUD cost to complete, respectively.  
 Three beams for each H&N case and four beams for the CHDM case were selected. 
Figure 2-1 shows the beam arrangement of each plan for the CHDM patient. The beams 
selected by using the L2,1/2-GS term were spatially well separated. In comparison, the 
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L2,1-GS term resulted in aggregated beams with both quadratic and LEUD cost terms, 
indicating a potential degeneracy issue with this group sparsity term. And the CG method 
tended to choose beams with short pathlengths to target. Interestingly, the beam 
orientations optimized by L2,1/2-GS were similar to the actual angles selected by an 
experienced dosimetrist in this CHDM case.  
  
MAN Quad L2,1/2-GS Quad L2,1-GS 
LEUD L2,1/2-GS LEUD L2,1-GS CG 
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Figure 2-1: The beam arrangement of each plan for the CHDM patient. 
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Figure 2-2 shows the DVHs comparison between GS plans and MAN plan for each patient. 
Table 2-2 and Table 2-3 show the OAR statistics for each patient with quadratic cost and 
LEUD cost, respectively. On average, the L2,1/2-GS plans reduced the OAR [Dmean, Dmax] 
from MAN plans by [2.4%, 4.2%] and [2.3%, 3.8%] of the prescription dose for Quad and 
LEUD cost, respectively, while achieving comparable target coverage.   
 The L2,1-GS method produced competitive plan for H&N#1 and CHDM case, but 
led to worse and OAR dose over MAN plan for H&N#2 and H&N#3 case with similar PTV 
coverage. The average decrease in OAR [Dmean, Dmax] from MAN plans are [-1.0%, 0.1%] 
and [-1.2%, 1.2%] of the prescription dose for Quad and LEUD cost, respectively. 
Case 
L2,1/2 - MAN (GyRBE) L2,1 - MAN (GyRBE) 
Dmean Dmax Dmean Dmax 
Largest 
Value 
Average 
Value 
Largest 
Value 
Average 
Value 
Largest 
Value 
Average 
Value 
Largest 
Value 
Average 
Value 
H&N#1 
-1.2 
L 
Parotid 
-0.5 
-8.1 
Brainstem 
-2.8 
-3.1 
L 
Parotid 
-0.5 
-10.4 
L 
Parotid 
-2.6 
H&N#2 
-3.8 
Carotid 
-1.0 
-2.1 
Pharynx 
-1.0 
-0.2 
Larynx 
+0.8 
-1.5 
Larynx 
+0.9 
H&N#3 
-20.1 
TMJ 
-3.0 
-34.6 
R Opt Nrv 
-3.9 
-26.3 
TMJ 
+1.8 
-35.1 
TMJ 
+3.7 
CHDM 
-7.0 
L 
Cochlea 
-0.7 
-16.4 
L Cochlea 
-1.0 
-4.5 
L 
Cochlea 
+0.4 
-11.2 
L 
Cochlea 
-1.2 
Table 2-2: The difference of OAR doses between GS and MAN plans for all patients under 
Quad cost. A negative sign represents a reduction of dose in GS plan from MAN plan. 
 
Cases 
L2,1/2 - MAN (GyRBE) L2,1 - MAN (GyRBE) 
Dmean Dmax Dmean Dmax 
Largest 
Value 
Average 
Value 
Largest 
Value 
Average 
Value 
Largest 
Value 
Average 
Value 
Largest 
Value 
Average 
Value 
H&N#1 -1.5 -1.0 -6.75 -2.8 -0.98 -0.1 -8.9 -1.9 
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L 
Parotid 
Pharynx Pharynx Pharynx 
H&N#2 
-0.8 
Carotid 
-0.3 
-3.75 
Larynx 
-1.1 
0.04 
Mandible 
+2.2 
1.0 
Mandible 
+4.1 
H&N#3 
-16.2 
TMJ 
-2.5 
-28.83 
R Opt 
Nrv 
-2.3 
-19.52 
TMJ 
+0.8 
-21.0 
R Opt 
Nrv 
+1.0 
CHDM 
-8.8 
R 
Cochlea 
-1.4 
-10.99 
R 
Cochlea 
-1.0 
-8.89 
R Opt 
Nrv 
-1.3 
-9.6 
R cochlea 
-1.3 
Table 2-3: The difference of OAR doses between GS and MAN plans for all patients under 
LEUD cost. A negative sign represents a reduction of dose in GS plan from MAN plan. 
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Figure 2-2: DVH comparison of the MAN plan (solid line), L2,1/2-GS plan (dotted line) and 
L2,1-GS plan (dashed line) for each patient. The plans with quadratic cost are listed on the 
left column and the plans with LEUD cost are on the right column. 
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 The limitation of using L2,1-norm can be observed from the final value of dose 
fidelity cost. Figure 2-3 compares the convergence between L2,1/2-norm and L2,1-norm 
group sparsity for the H&N#3 case. For the quadratic and LEUD cost functions, the L2,1/2-
norm group sparsity method converged after about 800 iterations and 1800 iterations 
respectively. In contrast, with an L2,1-norm group sparsity term, the problem quickly 
converged within 30 iterations and 80 iterations under the quadratic and LEUD cost 
functions, respectively. However, the converged dose fidelity function values using the 
L2,1-norm are substantially greater than the corresponding values of using the L2,1/2-
norm (~105 for L2,1 vs. ~102 for L2,1/2), showing a larger deviation from the prescription 
dose using L2,1-norm in this case. 
 
Figure 2-3: The convergence comparison between L2,1/2-norm (solid) and L2,1-norm 
(dotted) group sparsity for case H&N#3. Left is Quad-GS and right is LEUD-GS. The blue 
curve shows the value of entire cost function and the red curve shows the value of dose 
fidelity term. 
 The DVHs comparison between L2,1/2-GS plans and CG plans is shown in Figure 
2-4. In all H&N cases, the CG method produced plans with similar PTV coverage as L2,1/2-
GS method, but the OAR doses were inferior to the group sparsity algorithm. In the CHDM 
case, the CG plan performed comparably with the L2,1/2-GS plan with regard to PTV and 
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OAR dose. The CG methods reduced the mean dose to brainstem by 9.8Gy over L2,1/2-GS 
plan by forcing all beams entering from the anterior direction, increasing the risk of 
exposing the eyes to high dose with slight positioning error.   
 
Figure 2-4: DVH comparison between L2,1/2-GS plan (solid) and the CG plan (dotted) for 
each patient. 
2.4 Discussion 
 This work introduces a group sparsity based IMPT optimization method that 
simultaneously selects beams and optimizes the fluence map. In addition to the superior 
dosimetry compared with plans using manually selected beams, the planning method using 
optimized beams reduces the dependence on the individual operators who select beams 
based on experience and intuition.  
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 Compared to the earlier coplanar X-ray optimization study using group sparsity47, 
the current work expands its scope in several ways. This is a new application to the IMPT 
problem, which is intrinsically a higher-dimensional optimization problem than IMXT due 
to the additional modulation in the depth direction. The number of candidate beams in this 
study is an order of magnitude larger than in the original IMXT BOO study that used only 
72 candidate beams. The optimization solver used in the original study was based on 
ADMM and is not well suited to the current much larger IMPT BOO problem, because the 
linear systems that ADMM requires to be solved at each iteration would be intractably 
large. Therefore, we developed an approach based on FISTA, which requires only matrix-
vector multiplications involving the dose-calculation matrix. To enable the use of FISTA, we 
derived several key proximal operators. FISTA has been shown to have an optimal 
convergence rate of 𝑂(1 𝑘2⁄ ) among first-order methods56, and the numerical results 
demonstrate that FISTA is able to solve the large scale optimization problem in a clinically 
acceptable time. Although standard convergence results for FISTA assume that both 𝑓 and 
𝑔 are convex56, we have found that FISTA converged to a good solution even in the case of 
using the nonconvex L2,1/2-norm group sparsity penalty. 
 In this study, two different group sparsity terms, L2,1 and L2,1/2 norms, were 
compared for the IMPT BOO problem. Although the L2,1-norm is convex and offers certain 
computational advantages, it leads to suboptimal  dosimetry and tends to converge to a 
worse fidelity value when compared against the nonconvex L2,1/2-norm group sparsity 
term. Therefore, in this case, the ability to avoid degeneracy and select spatially separate 
beams appears to be dosimetrically advantageous. This finding shows that while the group 
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sparsity method is well suited to solve the BOO problem, the selection of the sparsity 
function is a subtle point that can make a critical difference. 
 The group sparsity beam orientation optimization method was tested on two 
different dose fidelity functions: quadratic and LEUD terms. Compared to the quadratic 
dose fidelity term, the LEUD cost function with a combination of mean and maximum dose 
constraints is easier to tune to achieve desired DVHs. This is reflected in the process of 
creating plans for the four cases in this study: the quadratic L2,1/2-GS method took on 
average 9-10 rounds of parameter tuning, and the LEUD method took 4-5 rounds. The 
advantage of quadratic dose fidelity function is that while the structure parameters need to 
be tuned, the group sparsity regularization weighting parameter remains constant for a 
specific number of beams. In comparison, with LEUD dose fidelity, the group sparsity 
regularization weight is sensitive to the structure weighting parameter changes, requiring 
additional adjustment to maintain the desired number of beams. Quadratic dose fidelity 
also resulted in, on average, more sparse scanning spots.  
 The group sparsity BOO method was also compared against the greedy column 
generation BOO algorithm. The results show the GS method produces comparable or 
superior plans over CG. Specifically, the CG method tends to select aggregated beams with 
short pathlengths to the target, such as the anterior beams in the CHDM case. The result 
indicates degeneracy that did not present in the IMXT BOO solution, possibly due to the 
substantial difference in dose distribution between the first proton beam and photon beam. 
Additional heuristics, such as minimal separating between selected beams, may be 
enforced to ameliorate the problem. 
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 The dose matrix size is determined by the target, which is limited to be 
approximately 110 cm3 to fit the calculation into a desktop with 64GB memory. For more 
general IMPT cases with larger tumor targets, either workstations with substantially larger 
memory or methods to intelligently reduce the dose matrix size without impacting plan 
quality are needed. These methods include (1) non-uniform sampling resolution with a 
higher resolution in the target and nearby organs, and lower resolution in the volumes that 
are considered less critical and faraway from the target, (2) clustering of the proton pencil 
beam dose matrices, and (3) using heuristics to reduce the number of candidate beams. We 
will investigate these directions for more general integrated BOO and scanning-spot 
optimization problems. 
2.5 Conclusion 
 This work shows the first IMPT planning approach that integrates non-coplanar 
beam orientation and fluence map optimization in a single mathematical framework, which 
was further formulated to have a computationally efficient solution despite its large 
problem size. This method resulted in dosimetrically competitive plans compared with the 
manual planning method and is less operator-dependent. It sets up the framework for the 
optimization problems that are handled in the subsequent studies. 
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3 APPLICATIONS OF GROUP 
SPARSITY REGULARIZATION 
FOR PROTON THERAPY 
3.1 Fraction-Variant Beam Orientation Optimization for 
IMPT 
3.1.1 Introduction 
 Different from X-ray therapy that found success in using more beams and arcs, 
proton therapy is conventionally limited to fewer beams due to three reasons. First, 
because of the unique physics of proton beams, it is feasible to achieve acceptable normal 
tissue sparing using fewer beams6,15. Second, using fewer beams spares larger normal 
tissue volumes from low-dose radiation exposure, which is one of the main benefit of 
proton therapy. Third, the proton treatment time is expensive; thus, it is economically 
desirable to use as few beams as possible to improve throughput. In today’s practice, it is 
typical to use two to four beams in IMPT. 
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 Nevertheless, sparing of organs adjacent to the targets can still benefit from using 
more proton beams. Studies have shown better OARs sparing in three to four-beam plans 
compared with 2-beam plans46. The addition of non-coplanar beams would also improve 
the plan quality35. Further increase in the number of beams to form arc delivery may lead 
to substantial improvement in dose conformity and adjacent organ sparing36,38,57–64. On the 
other hand, using a larger number of beams in IMPT can be impractical. Spot-scanning 
proton arc therapy is not clinically deliverable and will likely be limited to selected proton 
delivery systems. For static beam IMPT, the time to deliver more than four beams in single 
treatment fraction is increasingly unaffordable, particularly in multi-room configurations 
when proton beams are shared among different treatment rooms or when increased setup 
time is needed for non-coplanar beams. 
 One solution to the apparent conflict between the number of beams and delivery 
efficiency is to use different groups of beams on different treatment days. For IMXT, 
approaches have been developed to allow for a large number of beams in the entire 
treatment while limiting the number of beams in a single fraction. Dink et al65 proposed a 
field rotation method, in which multiple sets of coplanar beams were interchanged 
between fractions using a mixed integer linear program. Results showed an improvement 
of dose objectives based on this time-varying method. O’Connor et al66 proposed to use 
group sparsity regularization to select different beam angles for different fractions out of a 
large number of non-coplanar candidates. This fraction-variant beam orientation 
optimization scheme showed that the same dosimetry as conventional plans could be 
achieved using half as many beams per fraction. 
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 In this study, we aim to investigate the dosimetric and delivery efficiency benefit of 
fraction-variant beam orientation optimization in IMPT and its potential to improve 
treatment delivery efficiency. 
3.1.2 Methods 
 The goal of fraction-variant BOO (FVBOO) framework is to select a small number of 
beams from the candidate set for each fraction in a single step, but allow variant beam 
angles from fraction-to-fraction. More importantly, the target dose homogeneity is 
maintained regardless of the number of beams per fraction to avoid undesirable hot or cold 
spots within each fraction.  
3.1.2.1 Problem formation 
 Let 𝐹 indicate the number of treatment fractions and assume each fraction sharing 
the same candidate beam set. The number of candidate beams in each fraction is 𝐵. The 
problem is formulated as the following objective function: 
minimize
𝒙
       ∑𝜔𝑖
𝑖∈𝒯
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𝐹
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subject to    𝒙 ≥ 0. 
Equation 3-1    
 In Equation 3-1, 𝒙𝑓,𝑏 is a vector representing the intensities of scanning spots of 
the 𝑏th candidate beam in the 𝑓th fraction. Then 𝒙𝑓 is the concatenation of the vectors 𝒙𝑓,𝑏 
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(for 𝑏 = 1,… , 𝐵), representing the spot intensities of fraction 𝑓, and 𝒙 is the concatenation 
of the vectors 𝒙𝑓 (for 𝑓 = 1,… , 𝐹),  indicating the entire intensity map. 
 𝐴𝑖  is the dose-calculation matrix for structure 𝑖 (𝑖 ∈ 𝒯 or 𝒪, where  𝒯 is the set of 
target volumes, and 𝒪 is the set of OARs). Each column of 𝐴𝑖  is the vectorized dose 
delivered to structure 𝑖 from one scanning spot of unit intensity.  Therefore, the product of 
𝐴𝑖  and 𝒙𝑓 is the dose delivered to structure 𝑖 in the 𝑓th fraction.  
 Equation 3-1 includes three terms. The first term is a fractional dose fidelity term 
on target volume. If the prescription dose to structure 𝑖 (𝑖 ∈ 𝒯) of the entire treatment is  
𝑝𝑖,the first term intends to penalize any dose deviation in each fraction from 𝑝𝑖 𝐹⁄ , which is 
the prescription dose per fraction. The second term captures cumulative dose fidelity on 
OARs, to encourage the dose to structure 𝑖 (𝑖 ∈ 𝒪) over the entire treatment not to exceed a 
maximum value 𝑚𝑖. 𝑚𝑖 can also be set to 0 so that any nonzero doses in the OARs are 
penalized. 𝜔𝑖 is a structure-specific weighting parameter. 
 The third term in Equation 3-1 is the non-convex group sparsity term developed in 
Chapter 2, used for beams selection. It groups the spots in the same candidate beam and 
same fraction in a L2,1/2 -norm term. With a proper value of weighting hyperparameter 𝛼𝑏 
of each beam 𝑏, most of the candidate beams in each fraction will be turned off, leaving a 
small active set, consisting of 1-4 active beams. Moreover, the non-convexity of the L2,1/2-
norm allows varying beam combinations in different fractions, making the BOO fraction-
variant.  
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3.1.2.2 Evaluations 
 This FVBOO method was tested on one patient with the base-of-skull tumor (BOS), 
one bilateral head-and-neck (H&N) patient, and one esophageal cancer (ESG) patient. For 
all patients, the treatment includes 30 fractions. For the BOS patient, an additional plan 
with 5-fractions (5f) was generated. This BOS case was not clinically treated with 5 
fractions, but the 5-fractions plans were created to test the ability of the FVBOO method for 
hypofractionated treatments. The initial candidate beams included 400~800 non-coplanar 
candidate beams. For each candidate beam, dose calculation for the scanning spots 
covering the PTV and a 5 mm margin was performed using  matRad51,52. The dose 
calculation resolution was 2.5×2.5×2.5 mm. The prescription dose, target volume, and the 
number of fractions for each patient are shown in Table 3-1. 
Case 
Prescription Dose 
(GyRBE) 
PTV Volume 
(cc) 
Number of fields 
in the FIBOO plan 
Number of  
fractions 
BOS 56 66.8 4 5, 30 
H&N 
PTV54 54 179.1 
3 30 
PTV60 60 204.4 
ESG 50 480.9 3 30 
Table 3-1: Prescription doses, PTV volumes, number of fields, and number of fractions for 
each patient 
 To determine the effectiveness, the FVBOO plans were compared with the plans 
with fixed beams throughout the treatment. The fixed beam plans, termed Fraction-
Invariant BOO (FIBOO) plans, were created using the group sparsity based BOO algorithm 
proposed in Chapter 2. Different from FVBOO that penalizes the dose of PTV in each 
individual fraction, FIBOO penalizes the cumulative PTV dose of all fractions. The number 
of beams per fraction used in the FIBOO plans is also listed in Table 3-1.  
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 To match the number of beams in the FIBOO plans, the parameter 𝛼𝑏 in Equation 
3-1 was tuned in the FVBOO plans. Different from the integer beam numbers in FIBOO, the 
average beam numbers in the matching FVBOO plans are either the same or slightly lower. 
FVBOO plans with further reduced average beams per fraction were also generated in 
either the 5f or 30f setting for the BOS patient to determine the feasibility of creating more 
efficient IMPT plans without compromising dosimetry.  
3.1.3 Results 
3.1.3.1 Runtime and selected beams 
 FVBOO planning was performed using an i7 CPU desktop at 4.2 GHz clock. The 
resultant average number of selected beams and the BOO runtime of each method are 
listed in Table 3-2.  
 For the BOS patient, under the 5-fractions (5f) setting, three FVBOO plans were 
generated, with an average number of beams per fraction (b/f) of 3.8, 3, and 1.8, 
respectively. The 3.8 b/f plan used a total of 19 beams, among which, 12 and 7 are used in 
single and multiple fractions, respectively. The 3 b/f plan reduced the number of total 
beams to 15 with 11 single-use beams. The 1.8 b/f plans further reduced the number of 
total beams to 9, respectively with 7 single-use beams. 
 In the 30-fractions (30f) setting, four FVBOO plans were generated for the BOS 
patient, with an average number of beams per fraction being 3.6, 2.8, 2, and 1.3, 
respectively. In the 3.6 b/f plan, 109 beams are selected with 22 being single-use. In the 2.8 
b/f, 2 b/f and 1.3 b/f plans, the total number of beams reduced to 84, 61 and 40, 
respectively, with 20 to 13 single-use beams. 
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 For the H&N and ESG patient, the 30f-FVBOO plan selected 90 (24 single-use) 
beams and 84 (36 single-use) beams, respectively. 
 As shown in Table 3-2, compared with the FIBOO, the runtime of FVBOO selecting 
similar number of beams per fraction is approximately 4 time longer for the 5f plans and 9-
20 times longer for 30f plans. In the worst case for the 30f ESG FVBOO plan with a PTV 
volume of 480cc, the runtime is close to 10 hours. The runtime was shortened by up to 
40% when the goal was to achieve fewer total and per fraction beams in FBVOO.  
Case 
Num. 
fractions 
Method 
Num. beams selected 
BOO runtime 
(min) Total Unique 
Avg. per 
fraction 
BOS 
5 
FIBOO 20 4 4 13.4 
FVBOO 
19 12 3.8 52.4 
15 11 3 36.5 
9 7 1.8 33.6 
30 
FIBOO 120 4 4 13.4 
FVBOO 
107 22 3.6 129.9 
84 20 2.8 118.5 
61 20 2 95.2 
40 13 1.3 72.3 
HN 30 
FIBOO 90 3 3 25.1 
FVBOO 90 24 3 500.8 
ESG 30 
FIBOO 90 3 3 34.0 
FVBOO 84 36 2.8 590.0 
Table 3-2: Number of fractions, total number of beams selected, number of unique beams 
selected, average number of beams selected per fraction, and BOO runtimes. 
3.1.3.2 FIBOO and FVBOO with similar number of beams per fraction  
 The FIBOO and FVBOO plans with a similar number of beams per fraction are first 
compared. The cumulative dose distributions for the 5f and 30f FVBOO plans are shown in 
Figure 3-1. These plans with different BOO methods and different numbers of active beams 
achieved similar PTV dose coverage. Several OARs are selected and the differences of their 
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mean and maximum doses between the FVOO plans and the FIBOO plans are presented in 
Figure 3-2. 
 For the 5f setting of the BOS patient, the 3.8 b/f plan achieves better OARs sparing 
compared with the FIBOO plan using four beams. The average reduction of [Dmean, Dmax] 
of the 3.8 b/f plans from the FIBOO plans were [0.9, 2.1] GyRBE.  
 For the 30f setting, the FVBOO plans of each patient achieve superior OARs sparing 
compared with the FIBOO plan with a similar number of  beams per fraction, with an 
average reduction of [Dmean, Dmax] of [1.9, 4.1] GyRBE. The maximal reduction to the 
Dmax for each patient is right optical nerve (10.4 GyRBE) for the BOS patient, spinal cord 
(10.9 GyRBE) for the H&N patient and  trachea (9.8 GyRBE) for the ESG patient.  
 The volumes of the patient body irradiated by 2, 5, 10 and 20 GyRBE are listed in 
Table 3-3. As expected, with more beams being used, the FVBOO plans resulted in a larger 
volume being irradiated by the 2 GyRBE low dose. However, V5 is actually lower with 
FVBOO in the H&N and ESG cases. 
Case Plan fractions V2 V5 V10 V20 
BOS 
FIBOO 5,30 1165.9 438 343.2 189 
FVBOO 
5 909.5 639.5 370.9 156.5 
30 962.9 683.1 367.7 162.5 
HN 
FIBOO 30 3819.7 3359.4 2650.4 1672.2 
FVBOO 30 4519.6 3315.6 2440.3 1641 
ESG 
FIBOO 30 5501.3 4757.5 3702.3 1748.2 
FVBOO 30 9782.9 4525.2 2358.6 1265.8 
Table 3-3: The V2, V5, V10, V20 GyRBE to the body in volume (cc). 
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Figure 3-1: The beam angles of the 30f FVBOO plans (left), and the DVH comparison of the 
30f FVBOO plans (solid) with the FIBOO plan (dotted) for the three patients. The FVBOO 
plans have the similar number of beams per fraction as FIBOO. 
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Figure 3-2: The difference of OAR Dmean (blue) and Dmax (red) in GyRBE of the FVBOO 
plans from the FIBOO plans. A negative value represents a reduction from the FIBOO plan, 
and a positive value represents an increase.   
 In addition to the cumulative doses, the dose distributions of individual fractions 
are presented. The DVH for each fraction of the 5f plans for the BOS patient and the first 5 
fractions of the 30f plans for every patient are shown in Figure 3-3. In Figure 3-3, the 
dotted lines are the fractional dose. The solid lines are the cumulative dose from all 
fractions re-scaled to the fractional prescription dose (divided by the number of fractions), 
drawn for comparison. Consistent with our planning goal, despite varying beams, the PTV 
is covered by a homogeneous dose in individual fractions. While all the cumulative plans 
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are normalized so D95% = 100% of the prescription dose, the D95% of CTV in all fraction 
has an average value of 99.6% and a standard deviation of 0.4%. 
 
Figure 3-3: DVH of each fraction in the FVBOO 5-fractions plan of the BOS patient and the 
DVH of the first 5 fraction in the FVBOO 30-fractions plan of each patient. The dotted lines 
are the fractional dose. The solid lines are the cumulative dose from all fractions re-scaled 
to the fractional prescription dose. 
3.1.3.3 Reduce the number of beams in FIBOO  
 For the BOS patient, the number of beams per fraction is further reduced from 
around 4 to around 1. The DVH and dose wash comparison with decreasing number of 
beams are shown in Figure 3-4. For the 5f setting, while the 3.8 b/f plan achieves the best 
OARs sparing, with an average reduction of [Dmean, Dmax] from the FIBOO plans of [0.85, 
2.08] GyRBE, the FVBOO plan with 3b/f achieves slightly better OARs sparing compared 
with the FIBOO, with an average reduction of [Dmean, Dmax] of [0.17, 1.45] GyRBE. The 1.8 
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b/f plan has worse OAR doses than FIBOO plan, except the sparing to the right eye and 
right retina. 
 
Figure 3-4: The DVH and dose wash using different number of beams for the BOS patient. 
(a) The DVH comparison of the 5f FVBOO plans (solid) with the FIBOO plan (dotted), and 
the cumulative dose distribution of the 5f FVBOO plans. (b) The DVH comparison of the 30f 
FVBOO plans (solid) with the FIBOO plan (dotted), and cumulative dose distribution of the 
30f FVBOO plans. (c) The dose wash of the FIBOO plan.  
 For the 30f setting,  when further reducing the beams per fraction, to 2.8 and 2, the 
FVBOO plan still achieves better OARs sparing compared with the FIBOO plans with more 
beams, with an average reduction of [Dmean, Dmax] of [1.7, 4.1] GyRBE for the 2.8 b/f plan 
and [1.3, 3.2] GyRBE for the 2 b/f plan. The average beam number of 1.3 is too low for 
FVBOO to compete with FIBOO using 4 beams. 
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3.1.4 Discussion 
 While traditional fractionated IMPT plans use fixed fields and fluence map to 
deliver the same dose distribution to the patient during the treatment sessions, this work 
describes a novel method to treat different fractions with varying beam angles and fluence 
maps. The fraction-variant beam orientation and fluence map are simultaneously obtained 
using an optimization framework integrating modified dose fidelity terms and a group 
sparsity term for beam selection. The FVBOO framework generates fractionated plans that 
allow the OAR doses to vary for superior cumulative sparing without compromising PTV 
dose homogeneity in individual fractions. Different from proton arc therapy relying on the 
proprietary hardware and control system, FVBOO can be delivered on all existing proton 
systems capable of IMPT.  
 Besides the ability to improve the cumulative dose distribution using a similar 
number of beams, FVBOO can reduce the number of beams used per fraction without 
compromising dosimetry. For example, in the 5-fraction scheme, a 3-beam FVBOO plan 
performs comparatively with a 4-beam FIBOO plan. In the 30 fraction scheme, a 2-beam 
FVBOO plan better spares OARs than the 4-beam FIBOO plan. Considering the slow gantry 
rotating speed and the fact that a beamline is usually shared between multiple gantry 
rooms, the use of fewer beams in a treatment fraction allows for reducing the patient 
treatment time and improve the patient throughput without compromising the treatment 
quality.  
 Moreover, this fraction-variant scheme can be complementary to FLASH therapy, 
which utilizes ultra-high dose rate to enhance therapeutic ratio67–69. While proton has 
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potential to achieve the FLASH dose rate for clinical treatment in a single field, the time 
between two beams cannot be substantially reduced. The proposed method would allow 
fewer beams to be used to shorten the total treatment time without compromising the 
physical dose distribution.  
 In the current problem formulation, the fractional dose of PTV and the cumulative 
dose of OARs are considered and penalized. Under this condition, the OARs doses in each 
fraction are not strictly constrained but naturally limited by the dose to the PTV. To avoid 
overdosing an OAR in a single fraction, an OAR fractional dose penalization can be similarly 
incorporated in the FVBOO Equation 3-1. 
 For the same reason, our FV approach is different from the spatiotemporal 
modulation proposed by Unkelbach et al70–72 that introduces a heterogeneous fractional 
tumor dose for the improved overall biologically equivalent dose (BED). By maintaining the 
same uniform tumor dose throughout the treatment course, out method does not need to 
assume a radiobiological model and is more compatible with the current clinical practice. 
 The ability to select variant beams for the FVBOO method relied on the non-convex 
L2,1/2-norm group sparsity. We derived the proximal function for the group sparsity term 
so Equation 3-1 can be solved by FISTA, which is by far more efficient than ADMM.  FISTA 
originally assumes the function convexity56. Nevertheless, we found that FISTA converged 
to a good solution even in the case of using the non-convex L2,1/2-norm group sparsity 
penalty35,66. In this particular case, we observed in the 30 fractions plans, only 20 out of 
109 total selected beams are single-use. This is possibly due to the local minima and 
initialization condition, which currently use random initialization, and that the 
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optimization is trapped in local minima. Besides the demonstrated dosimetric 
performance, further improvement may be possible by using a different initialization 
strategy. On the practical side, re-using the “good” beam angles can reduce the QA 
workload. The tradeoff between using more beams and using the best beams can be further 
explored. 
 FVBOO method would create a challenge in the measurement-based patient-
specific qualify assurance (PSQA), which needs to be performed for individual fractions 
instead of the entire plan. However, the hurdle may be overcome by adopting calculation 
73–75 and treatment log file analysis76–78 based PSQA. 
 Another challenge of FVBOO is its longer computational time. For the ESG case 
with a large PTV volume of 480cc, the FVBOO plan took about 10 hours in comparison to 
the 30 minutes used by FIBOO planning. On the other hand, the extra computational time 
can be unsupervised after adopting the same planning parameters from the FIBOO plan.  
 Similar to proton arc therapy, FVBOO improves the dose conformity and adjacent 
organ sparing at the cost of increased low dose bath to normal tissue, as shown by the 
increase V2 and V5. Therefore, the use of FVBOO has to consider individual clinical 
requirements to balance the need for high dose conformality (to spare adjacent OARs) and 
the need to minimize low-dose bath effects. Nevertheless, FVBOO offers an alternative 
option to the clinicians.  
3.1.5 Conclusion 
 This work demonstrates a new IMPT optimization approach to vary beam angles 
during different treatment sessions. It provides a solution to use few beams per fraction 
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but many more beams throughout the entire treatment to improve either the plan quality 
or treatment delivery efficiency. 
3.2 Integrating Biological Effectiveness into Beam 
Orientation Optimization for IMPT 
3.2.1 Introduction 
 In current proton therapy clinical practice, a constant relative biological 
effectiveness (RBE) value of 1.1 is used17–19, assuming proton therapy is 10% more 
effective than high-energy photons. However, the generic RBE of 1.1 is an averaged value at 
the center of a spread-out Bragg peak (SOBP) for 65-250 MeV proton of in-vivo systems18. 
The RBE can vary substantially along treatment fields (ranging from 1.0 to 1.6 in SOBP)27. 
RBE values also depend on several other factors, such as linear energy transfer (LET), 
tissue radiobiological properties (𝛼 and 𝛽 value), physical dose, and specific biological 
endpoint18,27,79. In addition, with the pencil beam scanning (PBS) technique replacing 
passive scattering to be the mainstream delivery modality, the biological doses potentially 
differ from the previous observation on passive scattering28,29, warranting further 
investigation in the universal use of RBE=1.1. 
 There have been concerns that using the generic RBE value in proton therapy can 
lead to underdosage in the target or underestimation of the normal tissue toxicities. Several 
empirical RBE calculation models have been proposed26,79–82 to more accurately predict the 
RBE values. Efforts have then been made to include the RBE-weighted dose into treatment 
planning83–86. However, the dependence of these models on fitting parameters and tissue 
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radiobiological properties introduces considerable uncertainties in RBE-weighted dose 
prediction, making it difficult to incorporate them into clinical treatment planning.  
 Alternatively, dose-averaged LET has been suggested as a surrogate for indirect 
biological optimization87. The increase of biological effectiveness from the entrance to the 
distal edge of the Bragg peak is largely due to the increase of LET towards the end of proton 
range. Although the relationship is nonlinear, RBE increases monotonically with LET26,27,79–
82, making LET a reasonable first order approximation of RBE. Moreover, in contrast to the 
large RBE estimation uncertainties, LET can be accurately calculated via analytical 
modeling88–91 or Monte Carlo simulation92–95. The LET values can then be utilized in multi-
field optimized Intensity-Modulated Proton Therapy (MFO-IMPT, shorted as IMPT)30,96. 
 Studies have been performed to incorporate dose-averaged LET into biological 
optimization of IMPT. Tseung et al97 and Fager et al98 used LET painting to directly 
optimize the biological dose instead of the physical dose, which was considered impractical. 
A safer and more acceptable strategy is to simultaneously optimize LET and physical dose. 
Works have be done to maximize the LET in the target or minimize the LET in the critical 
organs at risk (OARs), while achieving the physical prescription doses in the target and the 
OARs30,31,99–103. For example, Unkelbach et al30 suggested to reoptimize the product of LET 
and physical dose (LET×D) after obtaining an initial IMPT plan based on the physical dose. 
They showed reduced LET hot spots in the critical structures with little physical dose 
degradation.  
 However, existing LET or LET×D optimization is limited to fixed beams despite the 
significant implication of beam orientations on the LET distribution30–34. For example, if an 
OAR abuts the target in the distal edge of a proton beam, it is difficult to reduce the LET in 
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this OAR without compromising physical dose coverage. In clinical practice, a planner can 
avoid some of the undesirable beam orientations based on experience31–34, but evaluating 
all beam angles for their dosimetry, robustness, and LET values is a large computational 
task unsuited for human operators. A beam orientation optimization (BOO) algorithm for 
both physical and biological dose optimization is essential for IMPT but has not been 
developed. In this work, we expand the group sparsity BOO framework developed in 
Chapter 2 for IMPT biological dose optimization.  
3.2.2 Methods 
 This Biological effectiveness-coupled Beam Orientation Optimization (BioBOO) 
method aims to select proton beams and generate treatment plans with both superior 
physical dose distribution and biological dose sparing. The dose and LET product (LET×D) 
is used as a surrogate of biological dose. The optimization function is formulated with a 
dose fidelity term, a LET×D and a group sparsity term. The details are described as follows. 
3.2.2.1 Dose and LET product 
 As proposed by Unkelbach et al30, the RBE-weighted dose at voxel 𝑖, written as 𝑏𝑖, 
can be approximated by: 
𝑏𝑖 = 𝐷𝑖 + 𝑐𝐿𝐷𝑖 , 
Equation 3-2    
where 𝐷𝑖  is the physical dose delivered to voxel 𝑖, 𝐿𝐷𝑖 is the dose and LET product at voxel 
𝑖, and 𝑐 is a scaling factor. The two terms represent the physical and LET weighted doses, 
respectively. The scaling factor 𝑐 value is assumed 0.04 𝜇m/keV following the publication30. 
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 In order to formulate the optimization problem, two matrices, 𝐴 and 𝐿, are first 
defined. The matrix 𝐴 is the dose calculation matrix as defined in Section 2.2.1. The element 
in the 𝑖th row and 𝑗th column of matrix 𝐴, denoted as 𝑎𝑖𝑗, representing the physical dose 
contribution from the pencil beam 𝑗 of unit intensity to the voxel 𝑖. Matrix 𝐿 is the LET 
calculation matrix. Similar to 𝐴, the 𝑖𝑗th element in 𝐿, denoted as 𝑙𝑖𝑗, is the LET from the 
pencil beam 𝑗 to the voxel 𝑖 of unit intensity. Let 𝒙 be a vector representing the intensities 
of all the scanning spots, with 𝑥𝑗  indicating the intensity of 𝑗th spot, then the physical dose 
to voxel 𝑖 from all scanning spots is calculated as 
𝐷𝑖 =∑𝑎𝑖𝑗𝑥𝑗
𝑗
. 
Equation 3-3    
 The dose-averaged LET to voxel 𝑖 over all scanning spots is 
𝐿𝐸𝑇𝑖 =
1
𝐷𝑖
∑𝑙𝑖𝑗𝑎𝑖𝑗𝑥𝑗
𝑗
. 
Equation 3-4    
 Therefore, the product of dose and LET at voxel 𝑖 is: 
𝐿𝐸𝑇𝑖 × 𝐷𝑖 =∑𝑙𝑖𝑗𝑎𝑖𝑗𝑥𝑗
𝑗
. 
Equation 3-5    
 In matrix-vector representation, the vectorized physical dose in the patient 
volume, denoted as 𝐷, can be written as 
𝐷 = 𝐴𝒙. 
Equation 3-6    
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 The product of dose and LET in the patient volume, denoted as 𝐿𝐷, can be 
calculated as the following matrix and vector multiplication: 
𝐿𝐷 = (𝐿 ∘ 𝐴)𝒙, 
Equation 3-7    
where the symbol ‘∘’ represents element-wise multiplication. 
3.2.2.2 Problem formulation 
 In the BioBOO framework, the LET×D constraint is incorporated into the group 
sparsity based BOO to encourage selecting proton beams which minimize LET×D in the 
OARs, while maintaining LET×D to the target as well as achieving superior physical dose 
distribution. Assume ℬ is the set containing all the feasible candidate beams. The BioBOO 
problem is formulated as 
minimize
𝒙
  ∑𝜔𝑗‖𝐴𝑗𝒙 − 𝑝𝑗‖2
2
𝑗∈𝒯
+∑𝜔𝑗‖𝐴𝑗𝒙‖2
2
𝑗∈𝒪
   
+∑𝛽𝑘 ‖((𝐿𝐷)𝑘
ref − (𝐿 ∘ 𝐴)𝑘𝒙)+‖2
2
𝑘∈𝒯
+∑𝛽𝑘‖(𝐿 ∘ 𝐴)𝑘𝒙‖2
2
𝑘∈𝒪
 
+∑𝛼𝑏‖𝒙𝑏‖2
1/2
𝑏∈ℬ
 
subject to    𝒙 ≥ 0, 
Equation 3-8    
where 𝒙𝑏 is the fluence map candidate beam 𝑏, so the optimization variable and 𝒙 is the 
concatenation of all the vectors 𝑥𝑏  (𝑏 ∈ ℬ). The dose calculation matrix 𝐴 and LET 
calculation matrix 𝐿 include all the candidate beams along the column direction.  𝒯 is the 
set including the target volumes and 𝒪 is the set including the OARs. 
 48 
 The first two terms in Equation 3-8 are the conventional physical dose fidelity 
term similar to Equation 2-3. The first term penalizes the dose deviation of target 𝑗 from 
prescription dose 𝑝𝑗 , to ensure a homogeneous physical dose distribution in the target. The 
second term penalizes any non-zero doses in the OARs, to reduce the doses delivered to the 
OARs. The third and fourth terms together are the LET×D conditions. The third term 
encourages the LET×D values in the target 𝑘 to be greater than (𝐿𝐷)𝑘
ref, to prevent cold 
spots in the biological dose. The fourth term minimizes the LET×D values in the OARs. 𝜔𝑗  
and 𝛽𝑘 are the structure weighting hyperparameters for dose and LET×D constraints, 
respectively. The last term  ∑ 𝛼𝑏‖𝒙𝑏‖2
1/2
𝑏∈ℬ  is the L2,1/2-norm group sparsity term defined 
in Section 2.2.1 for selecting beams.  
 Without the third and fourth terms penalizing LET×D, the Equation 3-8 describes 
the group sparsity based BOO framework proposed in Chapter 2, only ensuring physical 
dose sparing. After adding these two terms, proton beam angles and treatment plans are 
generated simultaneously with optimum physical and biological dose sparing. FISTA56 is 
used to solve this non-differentiable problem.  
3.2.2.3 Evaluations 
 Three patients with skull base tumor (SBT) and three patients with bilateral head-
and-neck (H&N) cancer were tested. The candidate beam set included 700 to 800 non-
coplanar beams for the SBT patients, and approximately 600 beams for the H&N patients. 
For each candidate beam, dose and LET calculation for the scanning spots covering the PTV 
(planning target volume) and a 5 mm margin was performed by  matRad51,52. The dose 
calculation matrix 𝐴 and LET calculation matrix 𝐿 including all feasible candidate beams 
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were hence generated. The calculation resolution was 2.5×2.5×2.5 mm3. Since robust 
optimization is not considered in this work yet, the PTV was set as the optimization target. 
The prescription dose, target volume, and average spot count per beam for each patient are 
shown in Table 3-4.  
Case 
Prescription Dose 
(GyRBE) 
PTV Volume 
(cc) 
Average Spots 
Number per Beam 
SBT #1 56 66.80 2537 
SBT #2 70 70.26 2650 
SBT #3 
PTV6300 63 128.86 
4071 
PTV7400 74 26.58 
H&N #1 
PTV5400 54 257.41 
10065 PTV6000 60 274.38 
PTV6300 63 121.52 
H&N #2 
PTV5400 54 205.76 
10077 
PTV6000 60 210.43 
H&N #3 
PTV5400 54 206.10 
9433 PTV6000 60 173.56 
PTV6300 63 21.20 
Table 3-4: Prescription doses, PTV volumes and average number of spots per beam for each 
patient. 
 For comparison, in addition to the BioBOO plan, the following four plans were also 
generated for each patient: 1) conventional plan optimizing physical dose with manually 
selected beams (MAN); 2) the same MAN plan reoptimized with additional cLET×D 
constraint (BioMAN); 3) the plan generated by group sparsity based BOO with only 
physical dose constraint (GSBOO); 4) the same GSBOO plan reoptimized with additional 
cLET×D constraint (GSBOO_BioFMO, with FMO representing fluence map optimization). 
The differences of these plans are listed in Table 3-5. 
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Acronym 
Initial optimization Re-optimized 
with cLET×D 
constraint ? 
Beam selection 
method 
Physical dose 
constraint ? 
cLET×D 
constraint ? 
MAN Manual selection Yes No No 
BioMAN Manual selection Yes No Yes 
GSBOO Group sparsity Yes No No 
GSBOO_BioFMO Group sparsity Yes No Yes 
BioBOO Group sparsity Yes Yes No 
Table 3-5: Acronyms of different methods and the comparison. 
 For all plans, the goal of physical dose optimization is the same as conventional 
treatment planning. We set the physical dose distribution in the target to be homogeneous 
and a constant RBE value of 1.1 was used. The plans are normalized so that 95% of the 
target volume receives the prescribed physical dose, which is  
prescription dose
1.1
. For the 
biological component, since there is no predefined reference value for cLET × D that can be 
used, we set the  𝑐(𝐿𝐷)ref of the PTVs to the mean cLET × D value of the PTVs in the MAN 
plans. 
3.2.3 Results 
3.2.3.1 Runtime and selected beams 
 The calculation and optimization were performed on a Xeon 14-core CPU server 
operating at 2.40 GHz clock. To calculate the dose and LET of all feasible candidate beams, 
the Matlab Parallel Computing Toolbox was used to accelerate the computation. The times 
spent on the dose and LET calculation and the BOO runtime for the GSBOO and BioBOO 
plans are listed in Table 3-6. The couch and gantry angles for the beams from manual 
selection, GSBOO, and BioBOO, are also listed in Table 3-6. In matRad, the physical dose 
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calculation and LET calculation share the same ray-tracing procedure, which is also the 
most time-consuming step. Therefore, the total time for dose and LET calculation is shown. 
With the analytical calculation model and parallel computing, the total time for dose and 
LET calculation is between 10 to 60 min depending on the target size. While the GSBOO 
process with only physical dose constraint took about 20-70 minutes to complete, the 
BioBOO process with additional cLET×D constraint increased the BOO time by 30-80%.  
Case  
Dose, LET 
calculation 
time (min) 
BOO runtime 
(min) 
Selected beam angles (gantry, couch) 
GSBOO BioBOO MAN GSBOO BioBOO 
SBT #1 11 21 31 
(60,275)(270
,0) 
(90,0) 
(303,62)(97,324) 
(42,37) 
(288,45)(123,33
1) 
(42,37) 
SBT #2 16 25 46 
(60,275)(270
,0) 
(90,0)(180,0) 
(62,339)(341,19) 
(300,353)(17,46) 
(95,281)(60,332) 
(137,18)(276,34
2) 
SBT #3 21 31 56 
(60,275)(270
,0) 
(90,0)(180,0) 
(66,0)(84,0) 
(270,342)(316,3
14) 
(268,84)(276,0) 
(67,20)(33,66) 
H&N 
#1 
56 70 101 
(0,0)(160,0) 
(200,0) 
(51,320)(154,29
3) 
(330,321) 
(188,45)(38,20) 
(330,321) 
H&N 
#2 
58 55 73 
(0,0)(160,0) 
(200,0) 
(322,20)(167,29
6) 
(212,23) 
(167,296)(212,2
3) 
(324,301) 
H&N 
#3 
55 62 89 
(0,0)(160,0) 
(200,0) 
(149,348)(193,2
7) 
(41,50) 
(149,348)(188,4
5) 
(31,76) 
Table 3-6: Optimization time and selected beam angles for each patient. 
3.2.3.2 SBT cases 
 BioBOO is compared with MAN and GSBOO. The dose volume histograms and 
cLEDxD volume histograms for the three SBT patients comparing MAN, BioMAN and 
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BioBOO are shown in Figure 3-5 and that comparing GSBOO, GSBOO_BioFMO and BioBOO 
are shown in Figure 3-6. The differences in dose and LET×D of BioMAN, GSBOO_BioFMO 
and BioBOO plan from the MAN plan for some OARs are shown in Figure 3-7. 
 
Figure 3-5: Comparison of dose and cLEDxD between BioBOO (solid), BioMAN (dotted) and 
MAN (dashed) for the SBT patients. Left column is the dose volume histogram and right 
column is the cLEDxD volume histogram. 
 Qualitatively, all the five methods achieved similar PTV dose coverage. In the 
GSBOO plans, the cLET×D values of the PTVs were not guaranteed, which can be higher 
(SBT #1) or lower (SBT #2) than the MAN plan. With the LET×D constraint in the BioMAN, 
BioBOO and GSBOO_BioFMO plans, the mean and maximal values of LET×D of the PTVs 
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were similar compared with the MAN plans, but the minimal values of PTV LET×D were 
improved relative to the MAN plans. 
 
Figure 3-6: Comparison of dose and cLEDxD between BioBOO (solid), GSBOO_BioFMO 
(dotted) and GSBOO (dashed) for the SBT patients. Left column is the dose volume 
histogram and right column is the cLEDxD volume histogram. 
 Reoptimizing the MAN plan based on the proposed LET×D constraint resulted in 
lower LET×D of the OARs while maintaining similar physical dose distribution. In the 
GSBOO plans, where only physical dose constraint was considered, the physical dose was 
improved, but the sparing of LET×D was not guaranteed. For example, the maximal cLET×D 
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of the left optical nerve for SBT #1 in the GSBOO plan was 2.4 Gy higher than the MAN plan. 
Reoptimizing LET×D based on the GSBOO plans leads to slightly degraded physical dose 
distribution and lower LET×D, but the LET×D sparing was not as good as BioMAN. On 
average, the GSBOO_BioFMO plans reduced [Dmean, Dmax] from the BioMAN plans by [3.8, 
4.5] GyRBE on average, but increasing [cLET×Dmean, cLET×Dmax] by [0.1, 0.4] Gy.  
 The BioBOO plans achieved better OARs dose sparing and further reduced the 
OARs LET×D. The physical dose was reduced in the BioBOO plans from the MAN plan for 
most considered OARs except the chiasm in SBT #1 and SBT #3, and the right optical nerve 
in SBT #2. Even for these structures that were not improved compared with MAN, the 
difference was smaller than 1 GyRBE. The structure with the largest reduction in the 
maximal doses from the MAN plans were left eye (9.1 GyRBE) for SBT #1, pharynx (13.8 
GyRBE) for SBT #2, and hippocampus (15.7 GyRBE) for SBT #3. The averaged reduction in 
[Dmean, Dmax] of the BioBOO plans from the MAN plans were [2.85, 4.6] GyRBE, while the 
averaged reduction of [Dmean, Dmax] of the BioMAN plans from the MAN plans were [0.1, 
0.5] GyRBE. 
 Meanwhile, even though the BioBOO method did not improve the physical dose for 
certain structures in the SBT cases, it further reduced the LET×D compared with BioMAN. 
For example, the maximal cLET×D of chiasm in the three cases were 1.5 Gy, 0.9 Gy and 1.0 
Gy lower than the BioMAN plans, respectively, while the physical dose were similar. 
Compared with the BioMAN plans, the structure with the largest reduction of maximal 
cLET×D by BioBOO in each case was right optical nerve (1.7 Gy) for SBT #1, pharynx (2.9 
Gy) for SBT #2, and brainstem (1.6 Gy) for SBT #3. The averaged reduction of 
[cLET×Dmean, cLET×Dmax] of the BioBOO plans from the MAN plans were [1.1, 2.9] Gy, 
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while the averaged reduction of [cLET×Dmean, cLET×Dmax] of the BioMAN plans from the 
MAN plans were [0.7, 1.7] Gy. 
 
Figure 3-7: The difference of OAR dose and cLET×D metrics of BioMAN, GSBOO_BioFMO 
and BioBOO from MAN for the three SBT patients. A negative sign represents a reduction 
from the MAN plan and a positive sign represents an increase.   
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3.2.3.3 H&N cases 
 The dose volume histograms and cLEDxD volume histograms for the three H&N 
patients comparing MAN, BioMAN, and BioBOO are shown in Figure 3-8 and that 
comparing GSBOO, GSBOO_BioFMO, and BioBOO are shown in Figure 3-9. The differences 
in dose and LET×D of BioMAN, GSBOO_BioFMO and BioBOO plans relative to the MAN plan 
for selected OARs are shown in Figure 3-10. 
 
Figure 3-8: Comparison of dose and cLEDxD between BioBOO (solid), BioMAN (dotted) and 
MAN (dashed) for the H&N patients. Left column is the dose volume histogram and right 
column is the cLEDxD volume histogram. 
 
 
H&N #1 
H&N #2 
H&N #3 
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Figure 3-9: Comparison of dose and cLEDxD between BioBOO (solid), GSBOO_BioFMO 
(dotted) and GSBOO (dashed) for the H&N patients. Left column is the dose volume 
histogram and right column is the cLEDxD volume histogram. 
 Similar to the SBT cases, all the five methods achieved similar PTV dose coverage 
and comparable cLET×D distribution. An improvement of minimal cLET×D is observed in 
the BioMAN, BioBOO and GSBOO_BioFMO plans from the MAN plans, indicating reduced 
cLET×D cold spots in the PTVs. Compared with BioMAN, GSBOO_BioFMO reduced [Dmean, 
Dmax] by [1.7, 2.6] GyRBE on average, with similar LET×D and an average increase of 
[cLET×Dmean, cLET×Dmax] by [-0.1, 0.1] Gy. 
 
H&N #1 
H&N #2 
H&N #3 
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Figure 3-10: The difference of OAR dose and cLET×D metrics of BioMAN, GSBOO_BioFMO 
and BioBOO from MAN for the three H&N patients. A negative sign represents a reduction 
from the MAN plan and a positive sign represents an increase.   
 The OARs doses in the BioBOO plans were consistently reduced compared with the 
MAN plans except the right submandibular gland in H&N #1 and H&N #3. The structure of 
the largest reduction of maximal dose from the MAN plan in each case was the right parotid 
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(5.9 GyRBE) for H&N #1, constrictors (4.6 GyRBE) for H&N #2, and larynx (4.4 GyRBE) for 
H&N #3. The averaged reduction of [Dmean, Dmax] of the BioBOO plans from the MAN 
plans were [0.9, 2.5] GyRBE, while on average the [Dmean, Dmax] of the BioMAN plans 
were increased by [0.5, 0.2] GyRBE from the MAN plans. 
 Even though the doses to the right submandibular gland in the three BioBOO plans 
were comparable to the MAN plans, an effective reduction of LET×D by the BioBOO method 
was observed. Compared with the BioMAN plans, the maximal cLET×D of the right 
submandibular gland in the three cases was 2.3 Gy, 2.2 Gy and 1.2 Gy lower in the BioBOO 
plans. The averaged reduction of [cLET×Dmean, cLET×Dmax] of the BioBOO plans from the 
MAN plans were [0.8, 2.6] Gy, while the averaged reduction of [cLET×Dmean, cLET×Dmax] 
of the BioMAN plans from the MAN plans were [0.3, 1.2] Gy. 
3.2.4 Discussion 
 Unexpected high LET-weighted pencil beam dose deposition inside a sensitive OAR 
has raised considerable concerns in IMPT plans. Although the beam direction strongly 
correlates with the distal proton biological effect, IMPT optimization may scatter high-LET 
beams throughout the target volume or sometimes within OARs. Manual selection of 
proton fields for multiple planning goals including optimal dosimetry, biological 
effectiveness and robustness is a computational task beyond the capability of human 
planners. To the best of our knowledge, this work describes the first mathematical 
framework and actual implementation that include biological effectiveness in IMPT beam 
orientation optimization. In contrast to the limited manual trial and error approach, the 
BioBOO framework performs a global search among all feasible candidate beams by solving 
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a group sparsity problem integrating physical dose objectives and biological dose 
constraints.  
 Compared with the previous approaches appending LET optimization to the 
physical dose optimization using manually selected beams, which were shown to reduce 
LET in the OARs at the cost of the physical dose30, BioBOO further reduced both the 
physical dose and LET×D in the OARs. The OAR dose and LET reduction was achieved 
while maintaining the physical target dose and LET×D coverage, eliminating concerns due 
to uncertain tumor radiobiology and RBE modeling. It is worth noting that the current 
framework is flexible to increase LET×D in the tumor for potentially greater tumor cell 
killing by setting the (𝐿𝐷)ref value in  Equation 3-8 higher. 
 A limitation of the current BioBOO framework is that the reference LET×D values 
for targets and normal tissues are unknown. Subsequently, the(𝐿𝐷)refand weighting 
hyperparameters for the LET×D constraints cannot be mechanistically determined. In this 
study, the (𝐿𝐷)ref value for the BioMAN and BioBOO plans of each patient was extracted 
from the corresponding conventional MAN plan so that we could compare the biological 
effectiveness with the MAN plan. However, in the clinical setting, the lack of reference 
values makes it difficult to directly use BioBOO for a new case. A potential solution is to set 
a typical SOBP single field plan before treatment planning and calculate the mean LET×D 
for the targets as the reference value.  Another alternative solution is that templates can be 
built for different sites, e.g., H&N and skull base in this study. Meanwhile, further preclinical 
and clinical research is needed for more quantitative integration of RBE modeling in 
treatment planning as recommended by AAPM TG-25619.  
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 Due to the prohibitively long time required to calculate dose and LET for over 500 
candidate beams using Monte Carlo, the current study used an analytical method. While the 
analytical method was shown to be acceptably accurate for dose calculation and BOO 
planning in our previous paper35,38, it has compromised accuracy for LET calculation due to 
reasons including failing to account for secondary protons88. Despite the limitation, the 
proof-of-principle study used the same analytical calculation engine across different 
methods for a fair comparison. Without changing the optimization framework, the dose 
calculation engine can be replaced by fast Monte Carlo or analytical calculation models, 
including secondary protons90 in future work.    
3.2.5 Conclusion 
 We developed a novel biological effectiveness-coupled BOO method for IMPT 
based on group sparsity regularization and LET×D constraint. Beams and plans with 
superior physical dose and biological OAR sparing are generated. 
3.3 A Novel Energy Layer Optimization Framework for 
Spot-Scanning Proton Arc Therapy36 
3.3.1 Introduction 
 To further reduce healthy tissue irradiation, the concept of proton arc therapy 
(PAT) has been proposed since 1997104–106, to combine the unique dose deposition curve of 
protons and the benefit of rotating beams. Passive-scattering based proton arc therapy is 
not practical for clinical application mainly due to the difficulty of changing beam-specific 
compensator and range modulation wheel during gantry rotation. But with the recent 
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development and increasing adoption of the spot-scanning technique4,107,108, the 
modulation is integrated into the gantry, making PAT technically viable.  
 Using the modern scanning nozzle, the modern proton systems deliver treatments 
spot-by-spot and layer-by-layer109–111. The time of spot scanning within the same energy 
layer is on the order of milliseconds, but it requires seconds to change energy to another 
layer112,113, particularly from low to high energies. The slow energy layer switch is mainly 
due to magnetic hysteresis accompanying changing magnetic field strengths in the energy 
selection system. The energy layer switching time (ELST) cannot be easily reduced. 
Therefore, for practical proton arc delivery, reduction of the energy switching steps is an 
essential consideration besides the dosimetric quality.  
 Different delivery methods have been proposed for spot-scanning proton arc 
therapy (SPAT), like multiple static fields114,115, distal edge tracking116,117, and single energy 
modulation118–120. However, these delivery methods either cannot perform continuous 
rotation-delivery, or fail to fully utilize the freedoms in spot-scanning techniques, and the 
delivery efficiency is not optimized. 
 Ding et al63 proposed a delivery-efficient and practical algorithm called SPArc. 
Similar to volumetric modulated arc therapy (VMAT)121, this greedy algorithm starts with a 
coarse sampling of beams, also known as control points, and iteratively increases the 
sampling frequency while redistributing the energy layers, until reaching the desired 
sampling frequency. By this method, 1-3 energy layers remain active at each control point, 
ensuring acceptable delivery time. Later this algorithm was updated to optimize the energy 
delivery sequence from high to low instead of arbitrary switching to further shorten the 
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delivery time122. Retrospective studies show the potential of SPArc plans that improve plan 
dosimetry compared with intensity-modulated proton therapy (IMPT) to lung cancer61,63, 
prostate cancer62, and whole-brain radiotherapy59. Recently, the first prototype of SPArc 
delivery was performed on a clinical IBA Proteus One proton machine, with a Proton 
Dynamic Arc Delivery (PDAD) module. It demonstrated the feasibility of SPArc treatment 
within the clinical requirements58.  
 However, in the current SPArc algorithm, the energy layer selection and 
optimization are greedy and heuristic. Due to the separate sequencing and plan 
optimization steps122, the optimality of the plan delivery efficiency and the dosimetric 
quality cannot be promised.  The alternating back-and-forth operation between the fluence 
map optimization and energy layer processing required for final plan creation is 
computationally inefficient.  
 To further improve SPAT, in this work, we present a novel optimization method to 
integrate energy layer selection and sequencing with scanning-spot optimization in a single 
framework, which affords a global search of all feasible energy layers and then 
simultaneously optimizes the energy sequence. The energy layer selection is achieved by 
the group sparsity regularization developed in Chapter 2. An energy-sequencing 
regularization is developed to improve the SPAT delivery efficiency. 
3.3.2 Methods 
 The proposed Energy Layer Optimization incorporated Spot-scanning Proton Arc 
Therapy (ELO-SPAT) optimization framework aims to select as few as possible energy 
layers from the available candidate layers and then encourage energy switch from high to 
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low, for a predefined control point. Considering the continuity in gantry rotating, the 
optimization goal to be exactly one active energy layer at each control point. 
 Motivated by this consideration, the ELO-SPAT framework is formulated with a 
dose fidelity, a group sparsity regularization, a log barrier regularization, and an energy-
sequencing (ES) penalty term. The details are described in the following sections. 
3.3.2.1  Notations 
 Before presenting the optimization framework, we establish the following 
notations.  
• 𝐵 is the number of static beams used as sampled control points. The fixed spacing of 
2.5° or 2°  is used in this study. 
• 𝐸 is the number of candidate energy layers in each beam. To simplify the notation, it 
is assumed that each beam has the same candidate energy layers. The infeasible 
layers can be eliminated during optimization. So the number of all candidate energy 
layers is 𝐵 × 𝐸. 
• The vector 𝒙𝑏𝑒 is the spot intensities of 𝑒th energy layer in 𝑏th beam. The length of 
𝒙𝑏𝑒, denoted as 𝑁𝑏𝑒, which is the number of scanning-spots in the specific layer, 
varies with beams and layers. 
• The vector 𝒙𝑏 is the concatenation of 𝒙𝑏𝑒 (for 𝑒 = 1,… , 𝐸) with increasing energy, 
representing the spot intensities of 𝑏th beam. And the vector 𝒙 is the concatenation 
of 𝒙𝑏 (for 𝑏 = 1,… , 𝐵), following the sequence of gantry rotation. 
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𝒙 =
[
 
 
 
 
 
𝒙1
𝒙2
⋮
𝒙𝑏
⋮
𝒙𝐵]
 
 
 
 
 
 and 𝒙𝑏 =
[
 
 
 
 
 
𝒙𝑏1
𝒙𝑏2
⋮
𝒙𝑏𝑒
⋮
𝒙𝑏𝐸]
 
 
 
 
 
.  
Equation 3-9    
• The vectors 𝒚 and  𝒚𝑏 are compact representations of 𝒙 and 𝒙𝑏𝑒 to eliminate the 
dimension of scanning-spot, with the element 𝑦𝑏𝑒 being the sum of all elements in 
𝒙𝑏𝑒. Therefore, all the 𝒚𝑏 (for 𝑏 = 1,… , 𝐵) are in the same length of 𝐸. 
𝒚 =
[
 
 
 
 
 
𝒚1
𝒚2
⋮
𝒚𝑏
⋮
𝒚𝐵]
 
 
 
 
 
, 𝒚𝑏 =
[
 
 
 
 
 
𝑦𝑏1
𝑦𝑏2
⋮
𝑦𝑏𝑒
⋮
𝑦𝑏𝐸]
 
 
 
 
 
 and 𝑦𝑏𝑒 =∑𝑥𝑏𝑒𝑖
𝑁𝑏𝑒
𝑖=1
. 
Equation 3-10    
Equation 3-15 can also be written as matrix-vector multiplication: 
𝒚 = 𝑊𝒙, 
Equation 3-11    
where  𝑊 is a summation matrix, to sum up 𝒙 along the spot dimension. 
• A new variable ?̃?𝑏 is defined by replacing each element in 𝒚𝑏 with 0 except the 
maximal element. 
?̃? =
[
 
 
 
 
?̃?1
⋮
?̃?𝑏
⋮
?̃?𝐵]
 
 
 
 
, ?̃?𝑏 =
[
 
 
 
 
?̃?𝑏1
⋮
?̃?𝑏𝑒
⋮
?̃?𝑏𝐵]
 
 
 
 
 and ?̃?𝑏𝑒 = {
𝑦𝑏𝑒 , if 𝑦𝑏𝑒 = max (𝒚𝑏)
0, otherwise
. 
Equation 3-12    
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• The matrix 𝐷𝑏
𝐵 is a discrete gradient operator for 𝑏th beam along the beam direction. 
For example,  𝐷𝑏
𝐵𝒚𝑏 is a vector of the intensity difference between 𝒚𝑏+1 and 𝒚𝑏,  
𝐷𝑏
𝐵𝒚𝑏 = 𝒚𝑏+1 − 𝒚𝑏. 
Equation 3-13    
• ?̃?𝑏
𝐵 is a specially designed gradient operator to make 
?̃?𝑏
𝐵𝒚𝑏 = 𝐷𝑏
𝐵?̃?𝑏 . 
Equation 3-14    
• The matrix 𝐷𝑏
𝐸  is a discrete gradient operator for 𝑏th beam along energy direction, 
while ignoring all zero elements. For example,   
𝐷𝑏
𝐸
[
 
 
 
 
 
 
 
 
0
⋮
𝑦𝑏𝑒1
0
𝑦𝑏𝑒2
⋮
0
𝑦𝑏𝑒3]
 
 
 
 
 
 
 
 
= [
𝑦𝑏𝑒2 − 𝑦𝑏𝑒1
𝑦𝑏𝑒3 − 𝑦𝑏𝑒2
] , and  𝑦𝑏𝑒1 , 𝑦𝑏𝑒2 , 𝑦𝑏𝑒3 ≠ 0 . 
Equation 3-15    
• 𝐴 is the dose-calculation matrix. 𝐴 contains all the spots from the entire 𝐵 × 𝐸 
candidate layers.  
• A sigmoid operator 𝒮 on a vector 𝒖 of length 𝐾, is defined as  
𝒮(𝒖) =
[
 
 
 
 
𝑠(𝑢1)
⋮
𝑠(𝑢𝑘)
⋮
𝑠(𝑢𝐾)]
 
 
 
 
 and 𝑠(𝑡) =  
2
1 + 𝑒−𝜂𝑡
− 1,  
Equation 3-16    
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where 𝑠(𝑡) is a modified sigmoid function, as a smooth approximation of sign function, and 
𝜂 controls the level of smoothness. The function of 𝒮 is to normalize each element in 𝒖 to 
−1, 0 or +1. 
3.3.2.2 Formulation of ELO-SPAT 
 The ELO-SPAT is formulated as follows: 
argmin   
𝒙
Γ(𝐴𝒙) +∑∑𝛼𝑏𝑒‖𝒙𝑏𝑒‖2
1/2
𝐸
𝑒=1
𝐵
𝑏=1
− 𝛽∑log (∑𝑦𝑏𝑒
𝐸
𝑒=1
)
𝐵
𝑏=1
 + 𝛾∑ℎ(𝐷𝑏
𝐸𝒮(?̃?𝑏
𝐵𝒚𝑏))
𝐵−1
𝑏=1
 
subject to    𝒙 ≥ 0, 
𝒚 = 𝑊𝒙. 
Equation 3-17    
 The first term is the dose fidelity term, penalizing the actual dose, calculated by 𝐴𝒙, 
from the prescription dose. The same quadratic function as Equation 2-3 is used in this 
study, but the choice of dose fidelity cost is flexible. The second term is the L2,1/2-norm 
group sparsity term. With proper tuning of the weighting hyperparameter 𝛼𝑏𝑒, the non-
convex ½ norm effectively turns off most candidate layers. But the term alone can result in 
aggregated layers in some beam blocks and leaving some control points with no layers 
active, which does not fully utilize the rotating beams. In the third term, a log barrier 
regularization function is used to distribute the selected layers to the whole gantry rotating 
range. The term sums up the intensity of each beam and penalizes the zero intensities, 
therefore forcing each beam to keep at least one layer selected. 𝛽 is the regularization 
parameter for the log barrier function. By picking a proper value of  𝛽 and setting 𝛼𝑏𝑒 large 
enough, one energy layer per beam can be ensured.  
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 The fourth term regularizes energy-sequencing (ES) with a weighting parameter 𝛾. 
ES regularization asymmetrically penalizes energy switching low-to-high harder than high-
to-low. The details of ES regularization can be found in Section 3.3.2.3.  
3.3.2.3 Energy-sequencing regularization 
 The method using the group sparsity to select a few layers out of the candidates is 
by gradually reducing the 𝒙𝑏𝑒 of the layer with a lower weight to zero during the iterations. 
As a result, in each beam, the layer with the maximal intensity is most likely kept in each 
iteration. Therefore, in the energy-sequencing term, instead of  𝒚𝑏, we control ?̃?𝑏, which 
only keeps the maximal element in 𝒚𝑏 and sets all others to zero, as defined in Section 
3.3.2.1. 
 To better understand how energy sequencing works, we consider two adjacent 
beams during gantry rotation, beam 𝑏, and beam 𝑏 + 1. Assume the only nonzero elements 
of  ?̃?𝑏 and  ?̃?𝑏+1  are  𝑦𝑏𝑒1 and 𝑦𝑏𝑒2 , respectively, at the position of 𝑒1 and 𝑒2. As shown in 
Figure 3-11, if 𝑒2 > 𝑒1, meaning energy going up from beam 𝑏 to beam 𝑏 + 1, the vector 
?̃?𝑏+1 − ?̃?𝑏, or  𝐷𝑏
𝐵?̃?𝑏, shows a pattern of transitioning from a negative value to a positive 
value, with possible zeros before, between, and after. A sigmoid operator 𝒮 is suited to 
normalize each nonzero element in  𝐷𝑏
𝐵?̃?𝑏 to −1 or +1.  
 With normalization, 𝒮(𝐷𝑏
𝐵?̃?𝑏) is a vector with only two non-zero elements −1, and 
+1, respectively. When the energy goes up, taking the difference of the non-zero elements 
along 𝑒 direction (the 𝐷𝑏
𝐸  operator defined in Section 3.3.2.1) results in +2. 
 Similarly, if the energy goes from high to low, the result of  𝐷𝑏
𝐸  operation on 
𝒮(𝐷𝑏
𝐵?̃?𝑏) is −2. Maintaining the same energy would result in zero values. 
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 The above process can be written as 𝐷𝑏
𝐸𝒮(𝐷𝑏
𝐵?̃?𝑏) or equivalently 𝐷𝑏
𝐸𝒮(?̃?𝑏
𝐵𝒚𝑏), as 
defined in Section 3.3.2.1. In summary, the value of 𝐷𝑏
𝐸𝒮(𝐷𝑏
𝐵?̃?𝑏) indicates the energy 
changing pattern between adjacent beams in the following relationship: 
𝐷𝑏
𝐸𝒮(?̃?𝑏
𝐵𝒚𝑏) = {
+2, energy switch − up,
−2,   energy switch − down,
0, energy unchanged.
 
Equation 3-18    
 For delivery efficiency, fewer energy switch-ups during gantry rotating are 
encouraged. Therefore, positive 𝐷𝑏
𝐸𝒮(?̃?𝑏
𝐵𝒚𝑏) is more heavily penalized. In this work, the 
energy switch-down is less penalized than staying unchanged for two reasons. First, energy 
switching down has a small impact on the total delivery time. For example, the switching-
down time is 0.6 s, according to the IBA Proton Dynamic Arc Delivery module, which is 
considered a negligible increase compared with staying unchanged in this study. Second, 
doing so encourages more layers to be used for better dosimetry. Mathematically, a one-
sided quadratic cost function is used to penalize energy switching. The cost function, ℎ(𝑡), 
is defined as: 
ℎ(𝑡) = {
1
4
(𝑡 + 2)2 − 1, if 𝑡 ≥ −2,
  −1, otherwise.
 
Equation 3-19    
 The quadratic term makes the function ℎ(𝑡) convex, smooth and differentiable, and 
the function definition is designed to give a value of 0 at 0 for simplicity.  
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Figure 3-11: Schematic workflow of energy-sequencing regularization. Two adjacent 
beams, beam b and beam b + 1, are shown, with the situation of energy switch-up in the 
middle column and energy switch-down in the right column.  (a) ỹb and ỹb+1 are shown as 
row vectors, while energy increases from left to right. ybe1  and ybe2 are the sole nonzero 
element of  ỹb and ỹb+1, respectively. (b) Db
Bỹb = ỹb+1 − ỹb. (c) Db
Bỹb is normalized to −1 or 
+1. (d) Take the gradient of 𝒮(Db
Bỹb) along e direction, which is the difference of the 
element at high e index and that at low e index. It yields a positive gradient when energy 
switches up and a negative gradient when energy switches down. (e) The positive gradient 
is penalized harder to encourage less energy switch-up. 
3.3.2.4 Evaluations 
 ELO-SPAT was tested on one frontal base-of-skull (BOS) patient, one chordoma 
(CHDM) patient with the simultaneous integrated boost, one bilateral head-and-neck 
(H&N) patient, and one lung (LNG) patient. A full arc was used for the H&N case, and a 
partial arc was used for the rest of the cases. Gantry rotation was assumed clockwise. The 
 71 
control points for individual beams were spaced 2° in the LNG case and 2.5° otherwise. 
Dose calculation for the scanning spots covering the PTV and a 5 mm margin was 
performed using matRad51,52. We assumed a constant RBE of 1.1. IMPT plans with 2~4 
manually selected beams were created for these tested patients for comparison. The 
prescription dose, target volume, arc range and IMPT beam angles for each patient are 
shown in Table 3-7 . 
 To investigate the effectiveness of ES regularization, we created two proton arc 
plans for each patient with or without ES regularization in Equation 3-17. In the latter plan, 
the energy layers were selected by group sparsity and log barrier regularization, but not 
sequenced.  
 We compared the ELO-SPAT plans against the arc plans created using the SPArc 
method proposed by Ding et al63. Because robustness is not considered yet in this work, the 
robust optimization used in SPArc is replaced with a conventional PTV-based fluence map 
optimization for a fair comparison. We created the SPArc plans using arc setting and dose 
calculation identical to ELO-SPAT. To match the two plans, in SPArc optimization, we 
pushed the number of layers per beam to be 1 for as many beams as possible, leaving only a 
few beams to have two energy layers. Similarly, we created SPArc plans with122 or without 
energy sequencing to compare with ELO-SPAT. The SPArc method with or without ES is 
denoted as SPArc-ES or SPArc-noES, and the ELO-SPAT method with or without ES is 
denoted as ELO-ES or ELO-noES. 
 All plans were normalized to deliver prescription dose to 95% of volume. The time 
spent on treatment planning and delivery of ELO-SPAT and SPArc were compared. For 
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delivery, because energy layer switching time (ELST) is the major factor affecting the total 
delivery time, we use the total time spent on energy layer switching as the surrogate. The 
times required for switching energy up, down and keeping it unchanged were 5.5 s, 0.6 s, 
and 0 s according to the IBA Proton Dynamic Arc Delivery (PDAD) module. A constant ELST 
of 2.1 s was also used for calculation according to the M.D. Anderson proton therapy 
system109 with a synchrotron accelerator. 
Case 
Prescription 
Dose 
(GyRBE) 
PTV 
Volume 
(cc) 
Arc angle (degree) 
IMPT (gantry, 
couch) 
angle (degree) Start 
angle 
Stop 
angle 
Spacing 
BOS 56 66.8 225 135 2.5 
(60, 273), (270, 0), 
(90, 0), (180, 0). 
CHDM 
PTV63 63 128.9 
225 135 2.5 
(60, 273), (270, 0), 
(90, 0), (180, 0). 
PTV74 74 26.6 
H&N 
PTV54 54 179.1 
180 180 2.5 
(0, 0), (160, 0), 
(200, 0). 
PTV60 60 204.4 
LNG 42 297.8 160 0 2 (180, 0), (315, 0). 
Table 3-7: Prescription doses, PTV volumes, arc range and IMPT beam angles for each 
patient. 
3.3.3 Results 
3.3.3.1 Optimization and delivery efficiency 
 The dose calculation and optimization were performed on a Xeon 28-core CPU 
server operating at 2.40 GHz clock, with Matlab and its Parallel Computing Toolbox. The 
energy layer delivery sequence for each patient using SPArc or ELO-SPAT with and without 
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energy sequencing is shown in Figure 3-12. The number of energy switches for different 
arc plans is plotted in Figure 3-13. The optimization time and expected delivery time are 
also shown in Figure 3-13.  
 Without ES regularization, although single energy layer at each control point is 
achieved, the energies are not ordered, resulting in 40 to 60 switch-up for the tested cases, 
adding a non-trivial amount of time to delivery. With ES regularization, the energy layer 
was sequenced to reduce the number of energy switch-up to fewer than 20, which are 
comparable to that of the SPArc plans with energy sequencing. Despite the similar number 
of energy up-switching, SPArc uses a regular sequencing pattern with the same number of 
down-switching between up-switchings. In comparison, ELO-SPAT sequencing patterns 
vary to meet dosimetric optimization needs. For the synchrotron plans, with a constant 
ELST of 2.1 s, the total ELST of ELO-ES plans was similar with the ELO-noES plans, with an 
averaged time reduction of 9%. For cyclotron plans, with an ELST-up of 5.5 s and ELST-
down of 0.6s, the total ELST was reduced to around 2 min in ELO-ES from the 4-7 min in 
ELO-noES, with an averaged reduction of 61%. Meanwhile, considering both the ELO-SPAT 
and SPArc plans with ES, the ELO plans had 10-30 more unchanged energies between 
adjacent control points compared with SPArc, therefore leading to an averaged reduction 
of total ELST time by 24% for the synchrotron plans and by 14% for the cyclotron plans. 
In addition to efficient delivery, the ELO-SPAT reduced the runtime of optimization by 84% 
on average, from the 0.5-2 hours in the SPArc plans to 5-30 min. 
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Figure 3-12: Energy layer delivery trajectory comparison between SPArc (blue) and ELO-
SPAT (red). The gantry rotates in clockwise following the angle of x-axis from left to right.  
The delivery sequences without ES are shown in the left column and with ES in the right 
column. 
 
Without ES with ES 
BOS 
CHDM 
LNG 
H&N 
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Figure 3-13: (a) Optimization runtime of the four arc plans. (b) The total ELST time of the 
four arc plans when the ELST time is 2.1s (left) and the ELST-up is 5.5 s and ELST-down is 
0.6s (right). (c) The number of energy switch up, down, and staying the same. The total 
number of energy switches is also plotted. 
3.3.3.2 Optimization and delivery efficiency 
 The DVH comparison of ELO-SPAT and SPArc without ES is shown in Figure 3-14, 
the DVH comparison of the two arc plans with ES is shown in Figure 3-15. The IMPT plan is 
plotted in both figures for comparison. The mean dose and max dose for several selected 
OARs were evaluated in the four arc plans and their differences from the IMPT plans are 
plotted in Figure 3-16. 
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 All compared plans achieved similar PTV dose coverage. Qualitatively, both the 
ELO and SPArc plans achieved better sparing compared with the IMPT plans for most 
OARs, either with or without ES. But in the lung case, the low dose region of the right lung 
is larger in the arc plans compared with the IMPT plans. 
 Without ES, the ELO-SPAT plans further improved the OAR sparing compared with 
the SPArc plans. Lower DVH lines are observed in the ELO-SPAT plans. For example, in the 
CHDM case, the maximum dose to the left and right cochleas were reduced by 8.1 GyRBE 
and 6.4 GyRBE, respectively. In the lung case, the maximum dose to the spinal cord was 
reduced by 5.6 GyRBE. On average, the ELO-SPAT plans without ES reduced the [Dmean, 
Dmax] of the OARs by [1.6, 3.3] GyRBE from the SPArc plans without ES. 
 While adding ES regularization, the dosimetry of the quality of ELO-SPAT plans 
degraded but was still slightly better than the SPArc plans with ES. For example, in the 
CHDM case, the maximum dose to the left and right cochleas were reduced by 2.8 GyRBE 
and 4.4 GyRBE, respectively. In the lung case, the maximum dose to the spinal cord was 
reduced by 2.6 GyRBE.  On average, the ELO-SPAT plans with ES reduced the [Dmean, 
Dmax] of the OARs by [1.4, 2.3] GyRBE from the SPArc with ES. 
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Figure 3-14: DVH comparison of plans without ES. The ELO-SPAT plan is in solid line, the 
SPArc plan is in dashed line, and the IMPT plan is in the dotted line. 
 
Figure 3-15: DVH comparison of plans with ES. The ELO-SPAT plan is in solid line, the 
SPArc plan is in the dashed line, and the IMPT plan is in the dotted line. 
 
BOS CHDM 
LNG H&N 
 
BOS CHDM 
LNG H&N 
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Figure 3-16: The difference of OAR Dmax (top) and Dmean (bottom) in the four arc plans 
from IMPT. A negative value represents a reduction from the IMPT plan, and a positive 
value represents an increase.   
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3.3.3.3 Convergence and effect of 𝜸 
 A convergence plot of the ELO-SPAT method, for the BOS patient, is shown in 
Figure 3-17. The cost of each component in Equation 3-17 during the iterations is also 
plotted. Dose fidelity, group sparsity, and log barrier all converged. The group sparsity is 
the component with the highest value because the tuning parameter 𝛼𝑏𝑒 need to be large 
enough to make only one layer selected per control point. Since the differential matrices 
𝐷𝑏
𝐸   and 𝐷𝑏
𝐵 were updated after every iteration, the cost on ES fluctuated during the 
iterations. But in general, the ES cost started from a high value, meaning lower delivery 
efficiency, converged to a low value, presenting higher delivery efficiency. 
 
Figure 3-17: Convergence plot of the ELO-SPAT method, for the BOS patient. The total cost 
and the cost components of dose fidelity, group sparsity, and log barrier are shown in the 
logarithm scale following the y-axis on the left. The ES cost is shown on a linear scale 
following the axis on the right. 
 Figure 3-18 shows how the ES weighting parameter 𝛾 affects the number of 
switch-up and the value of dose fidelity cost. Generally, when 𝛾 increases from zero, the 
number of energy switch-up decreases and the dose fidelity increases. When gamma 
reaches a certain value, such as 16 in this case, the number of switch-up plateaus, while the 
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fidelity cost is still in the trend of increasing. In this study, 𝛾 = 16 is picked for a minimum 
number of energy switch-up and the highest delivery efficiency. 
 
Figure 3-18: The number of energy switch-up and the value of final dose fidelity versus γ, 
for the BOS patient. 
3.3.4 Discussion 
 We present an integrated energy layer optimization method for scanning-spot 
proton arc therapy. The novel framework allows an integrated optimization of fluence map 
optimization, global search of candidate energy layers, and the delivery sequence. The 
energy-sequencing penalty is added as a soft regularization to dose fidelity term, thus 
providing a flexible trade-off between dosimetry and delivery speed. In this work, the final 
ELO-SPAT plans were selected as the ones with the lowest achievable number of energy 
switch-up for best delivery efficiency, with slight scarification of dosimetry. In clinical 
practice, the balance between dosimetry and delivery time can be tuned case-by-case. In 
the case of synchrotron where there is no difference between the time between energy 
layer switch up and down, the ES regularization can be removed for superior dosimetry.  
 The number of energy switch using the SPArc energy sequencing method is 
comparable to our optimization result, showing good performance with the heuristic 
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method. On the other hand, energy switching patterns are distinctly different. Compared 
with the regular SPArc pattern, the energy sequencing pattern using ELO-SPAT is flexible to 
take advantage of the patient and arc geometry. For example, for the patient with a frontal 
BOS tumor, when the gantry rotates in clockwise from posterior to anterior in the first half 
arc, the overall energies of the candidate layers decrease because the tumor becomes 
shallower from the beam’s eye view. The ELO-SPAT algorithm exploits the geometry and 
makes more switch-down before energy going up. The flexibility can facilitate future arc 
trajectory optimization to further enhance efficiency and dosimetry. 
 With a similar number of energy switch-up between the ELO-SPAT and SPArc 
plans, we observed 15-20% less total energy layer switching time in the ELO-SPAT method. 
This is because SPArc does not allow the energy to stay at the same level between control 
points due to the progressive sampling scheme and the way energy layers are distributed. 
Using ELO-SPAT, energy switching-down, and unchanged are both encouraged, thereby 
shortening the total energy layer switching time.  
 Another major benefit of ELO-SPAT is the significantly shortened optimization 
time by 5-10 fold from SPArc. In the progressive SPArc sampling scheme from coarse to 
fine control point resolution, repetitive fluence map optimization is required after either 
energy layer filtration or redistribution, resulting in long optimization runtime. In the ELO-
SPAT optimization, although the algorithm starts with all candidate layers, the number of 
active layers is gradually reduced to the desired number, shrinking the size of the dose 
matrix needed for calculation during computation, shortening the time for each iteration. 
Furthermore, ELO needs only one run to obtain the final delivery sequence and fluence 
map. The optimization was further accelerated by FISTA, which converges at an optimal 
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rate of 𝑂(1 𝑘2⁄ ) 56.  We expect additional acceleration using the graphics processing unit 
(GPU) platform and multi-resolution sampling of the dose matrix. 
 Due to the L2,1/2-norm for group sparsity and the sigmoid function for ES, 
Equation 3-17 is highly non-convex. Originally, FISTA has been used to solve convex 
problems. However, recent FISTA work35,38 and the convergence results (Figure 3-17) in 
this study suggest that FISTA can be used to solve certain non-convex problems with stable 
convergence. The differential matrices 𝐷𝑏
𝐸   and 𝐷𝑏
𝐵 need to be updated after every iteration, 
but their changes are gradual. Regardless of the ES cost fluctuation, the optimization 
converges in a few hundred iterations. On the other hand, because of the high non-
convexity and the need to update 𝐷𝑏
𝐸   and 𝐷𝑏
𝐵, a high weighting parameter on the ES term 
does not necessarily promote high delivery efficiency. As shown in Figure 3-18, the number 
of switch-up plateaus after reaching 16 for the BOS case. The main reason is that the 
problem is trapped in local minima due to the high non-convexity of the problem 
formulation. Still, the overall trend of decreasing the number of switch-up and increasing 
fidelity cost is observed can still be used to guide parameter tuning. While a random 
initialization is used in current work to assign the initial spots intensities during 
optimization, which is common but not necessarily optimal, other initialization schemes 
can be explored to improve the convergence of the optimization problem and overcome the 
local minima problem. 
 A limitation of the current ELO-SPAT algorithm is that only one energy layer 
allowed per control point for simplicity, while a few more layers could lead to better 
dosimetry with small scarification of delivery time. Without the energy-sequencing term, 
multiple layers are readily achievable by tuning the group sparsity term. However, allowing 
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multiple energy layers complicates energy sequencing in the current framework that only 
regulates the layer with maximal weight at each control point. This is a point for future 
improvement. 
 In the current problem formulation, the energy switching pattern is used as the 
surrogate of delivery time and the order of energy switching is penalized by a simple one-
sided quadratic Equation 3-19. In future work, Equation 3-19 can be designed to directly 
correlate the cost with machine-specific energy switching time, thereby allowing intuitive 
control of actual delivery time. Furthermore, the delivery time penalty can be incorporated 
as a hard constraint instead of the soft regularization in the current framework for the 
planner to specify the maximal permissible delivery time directly. 
3.3.5 Conclusion 
 We developed a computationally efficient spot-scanning proton arc method based 
on the group sparsity penalty and the novel energy-sequencing regularization. It solved 
energy layer selection and sequencing in an integrated optimization framework, generating 
proton plans with good dosimetry and high delivery efficiency. 
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4 INCORPORATING PHYSICAL 
DOSE ROBUSTNESS INTO 
BEAM ORIENTATION 
OPTIMIZATION 
4.1 Robust Fluence Map Optimization for IMPT with Soft 
Spot Sensitivity Regularization37 
4.1.1 Introduction 
 Due to the sharp drop-off at the proton Bragg peak2 and the beam-by-beam dose 
heterogeneity in the MFO plans49, IMPT is more susceptible to patient positioning errors or 
proton beam range uncertainties7–11. If the setup and range uncertainties are unaccounted 
for, dose to the tumor or OARs can substantially differ from what is indicated in the 
treatment plan. Different from X-ray treatment planning, the proton dose deviation can 
happen not only at the target boundaries but also inside the target, making traditional PTV 
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-based optimization, which expands the clinic target volume (CTV) by a safety margin, 
ineffective for IMPT48.  
 Several approaches have been developed to address this problem. Rather than a 
constant margin, a beam-specific PTV123 is introduced, to vary the margin based on the 
field and tissue property for passive scattering and single-field uniform dose IMPT (SFUD-
IMPT). Nevertheless, this approach is inapplicable to MFO-IMPT. A theoretically appealing 
way to account for uncertainties was reported to calculate the dose distribution under 
random perturbations and optimizes the expectation value of the objective function10,11. 
However, due to the large statistical sampling required, the probabilistic approach is too 
slow for practical use. An alternative probabilistic approach is analytical probabilistic 
modeling (APM)124,125, which uses a Gaussian pencil beam dose calculation algorithm to 
generate closed-form propagation of probability distributions to quantify uncertainty input 
for probabilistic optimization. APM is faster because scenario-sampling is not required, but 
estimation of the covariance requires non-trivial amount of computational resource that 
increases the optimization time. Furthermore, APM is incompatible with non-model-based 
pencil beam dose calculation, e.g., Monte Carlo, that is particularly important in handling 
the lateral dose profile and tissue heterogeneity in proton treatment planning. Coverage 
optimized planning126 is also a probabilistic treatment planning based method, which uses 
dose coverage histogram criteria to replace PTV margin and improves target dose coverage 
against geometric uncertainties, e.g. setup error. Nonetheless, range uncertainty is not 
considered in this method. Alternatively, Pflugfelder et al127 proposed to use a 
heterogeneity number to quantify lateral tissue heterogeneity of single scanning spot, and 
incorporated it in the inverse optimization to suppress the spots with a high heterogeneity 
 86 
number. This empirical method only considers the effect of tissue lateral heterogeneity to 
setup uncertainty without accounting for the range uncertainties. This method later 
pivoted towards beam angle selection128,129 , a separate problem from our current focus of 
robust scanning spot intensity optimization.  
 Presently, a class of methods referred to as “worst-case robust optimization” is 
more commonly used to handle setup and range uncertainties10,49,130–139. Instead of 
considering all possible variations, the worst-case method penalizes the maximal dose 
deviation for the estimated worst positioning and range estimation errors, to ensure 
acceptable dose distribution in these cases. In practice, the worst-case approach has 
reduced plan sensitivity to uncertainties, but on the other hand increased computational 
cost. Furthermore, the worst cases use generic estimation that may not be applicable to all 
cases. The actual patient anatomical and range uncertainties may still exceed the 
estimation, causing unexpected dosimetric deviations.  
 In this work, we aim to overcome these limitations and develop a novel 
mathematical framework to exploit the intricate balance between the proton scanning spot 
distribution, robustness and dose conformality. The plan robustness is incorporated as a 
sensitivity term in IMPT fluence map optimization, which minimizes the dose deviation 
from ideal dose distribution and penalizes the combination of scanning spots with high 
sensitivity. 
4.1.2 Method 
 The sensitivity-based robust optimization problem is formulated with a dose 
fidelity term and a robustness regularization term. The details are described as follows. 
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4.1.2.1  Sensitivity analysis 
 The dose calculation matrix, or the dose influence matrix, denoted as 𝐴, contains 
the vectorized dose information delivered to the patient volume from scanning spots of 
unit intensities. In this study, the position of individual scanning spots is denoted by the 
location of the Bragg peak in the patient volume. The sensitivity of a spot is determined by 
the magnitude of dose distribution for the perturbation due to patient position and range 
variations. To make the plan more resilient to changes, we penalize the spot position 
combinations with high sensitivity. The spatial dose gradient, which is used as a surrogate 
of spot sensitivity, is mathematically described as follows. 
 As shown in Figure 4-1, a coordinate system (𝒖𝑏 , 𝒗𝑏 , 𝒘𝑏) is first designated for the 
beam 𝑏, with the origin centered at the isocenter. 𝒖𝑏 represents the beam direction pointing from 
the source to the isocenter, and 𝒗𝑏 and 𝒘𝑏 are orthogonal vectors in the plane perpendicular to 
the beam direction. We define  𝒑𝑏,𝑖 as the spatial position of scanning-spot 𝑖 from beam 𝑏, which 
points from the isocenter to the position of its Bragg peak in the patient. 𝒂𝑏,𝑖  is the full 
dosimetric contribution of spot 𝑖 in beam 𝑏 to all voxels of the patient, embedded as a column 
vector in the dose calculation matrix 𝐴, and 𝒂𝑏 is the submatrix of 𝐴 that contains only the 𝒂𝑏,𝑖 
for all the spots in the same beam 𝑏. Then we evaluate the gradient field of 𝒂𝑏,𝑖 with respect to 
the spot position 𝒑, denoted as 𝛻𝒑𝒂𝑏,𝑖. If there are 𝑚 elements (meaning 𝑚 voxels in the 
patient volume) in the vector 𝒂𝑏,𝑖, then 𝛻𝒑𝒂𝑏,𝑖 is a 3 × 𝑚 matrix, with each row representing 
a directional derivative. 
 Then the directional derivatives of 𝛻𝒑𝒂𝑏,𝑖  along 𝒖𝑏 , 𝒗𝑏  and 𝒘𝑏  are in the respective 
functional forms: 
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𝐷𝒖𝑏𝒂𝑏,𝑖 = (𝛻𝒑𝒂𝑏,𝑖) ∙ 𝒖𝑏 , 
𝐷𝒗𝑏𝒂𝑏,𝑖 = (𝛻𝒑𝒂𝑏,𝑖) ∙ 𝒗𝑏 , 
𝐷𝒘𝑏𝒂𝑏,𝑖 = (𝛻𝒑𝒂𝑏,𝑖) ∙ 𝒘𝑏 . 
    Equation 4-1    
 This equation set evaluates the dose sensitivity level at each voxel from a specific 
scanning spot along the longitudinal direction (beam direction) and the lateral directions 
(orthogonal to beam direction). Since both 𝐷𝒗𝑏𝒂𝑏,𝑖 and  𝐷𝒘𝑏𝒂𝑏,𝑖 represent the lateral sensitivity, 
only 𝐷𝒖𝑏𝒂𝑏,𝑖 and  𝐷𝒗𝑏𝒂𝑏,𝑖 are used for optimization in the following sections. 
 We can obtain the vector specific to spot 𝑖 of beam 𝑏 in each direction, 𝒖𝑏 or 𝒗𝑏, by 
simply extracting column 𝑖 from 𝐷𝒖𝑏𝒂𝑏 or 𝐷𝒗𝑏𝒂𝑏, respectively. After performing this operation 
on every beam-specific submatrix of the 𝐴, we can obtain two sensitivity matrices, written as  
𝐷𝑢𝐴 and 𝐷𝑣𝐴.  
 
Figure 4-1: Diagram showing the coordinates and the vectors used in spot sensitivity 
calculation. The beam divergence due to spot lateral distance to the isocenter is 
exaggerated for illustration purposes. The actual proton system source-to-axis distance is 
substantially greater than the target size and the individual pencil beams in the same beam 
direction are nearly parallel.  
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4.1.2.2 Problem formation 
 As mentioned before, the spots are penalized based on their sensitivities. With the 
formation of sensitivity matrices along the beam direction and perpendicular to the beam 
direction, an intuitive approach is to penalize the L2,2-norm of 𝐷𝑘𝐴𝒙, (𝑘 ∈ {𝒖, 𝒗}), which is 
formulated as: 
minimize
𝒙
   Γ(𝐴𝒙) + 𝜆𝒖‖𝐷𝑢𝐴𝒙‖2
2 + 𝜆𝒗‖𝐷𝑣𝐴𝒙‖2
2, 
subject to   𝒙 ≥ 0, 
                                                                       Equation 4-2    
where 𝒙 is the optimization variable representing the scanning spot intensities,  Γ(𝐴𝒙) is 
the dose fidelity term penalizing the dose deviation from ideal dose distribution as defined 
in Section 2.2.1, and 𝜆𝒖 and  𝜆𝒗are the sensitivity regularization parameters.  
However, the matrix 𝐷𝑘𝐴𝒙, (𝑘 ∈ {𝒖, 𝒗}) has the same size as the matrix 𝐴, which makes it 
time- and memory-expensive to solve the problem Equation 4-2. To improve the 
computational efficiency, as suggested by Ungun et al.140, an L1-norm is used as a surrogate 
of the L2,2-norm and column clustering on the sensitivity matrix  is performed to reduce 
the problem size. The problem is then formulated as: 
minimize
𝒙
   Γ(𝐴𝒙) + ∑ 𝜆𝑘
𝑘∈{𝒖,𝒗}
‖𝐷𝑘𝐴𝒙‖1, 
subject to   𝒙 ≥ 0, 
                                                                       Equation 4-3    
 Then the absolute values of the rows of 𝐷𝑢𝐴 and 𝐷𝑣𝐴 are summed up, and the two 
resulting row vectors are transposed to produce the longitudinal and lateral sensitivity vectors, 
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denoted as 𝒔𝒖 and 𝒔𝒗, respectively. Then the sensitivity-regularized robust optimization 
problem is written as: 
minimize
𝒙
   Γ(𝐴𝒙) + ∑ 𝜆𝑘𝒔𝑘
𝑇𝒙
𝑘∈{𝒖,𝒗}
, 
subject to   𝒙 ≥ 0, 
                                                                       Equation 4-4    
 The initial large-scale matrix and vector multiplication in Equation 4-2 is reduced 
to a vector inner product, which is computationally inexpensive. Moreover,  Equation 4-4 is 
a convex problem and can be solved using FISTA56.  
4.1.2.3 Evaluation 
 This proposed Sensitivity Regularized (SenR) method was tested on three patients 
with skull base tumor (SBT) and three bilateral head-and-neck (H&N) patients, and was 
compared against conventional PTV-based optimization method (Conv) and voxel-wise 
worst-case optimization method (WC)10,49,132,134. The voxel-wise worst-case optimization 
considered nine scenarios, including one nominal scenario and 8 worst-case scenarios. The 
8 worst-case scenarios consist of (1) 6 setup uncertainties scenarios, by shifting the beam 
isocenter by ±3 mm along anteroposterior, superior-inferior, and mediolateral directions; 
(2) 2 range uncertainties scenarios, by scaling the CT number by ±3%. The worst-case 
method is solved by a first order primal-dual algorithm known as Chambolle-Pock 
algorithm141.  
 For every patient, the same beam arrangement, scanning spot population scheme 
and dose calculation engine were used for the three methods. The dose calculation for all 
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scanning spots covering the CTV and a 5 mm margin was performed by matRad51,52. The 
target volume for worst-case approach was chosen to be CTV, and the conventional method 
was planned based on the PTV, which was a 3-mm isotropic expansion of the CTV. Our 
sensitivity-regularized method was applied to both CTV and PTV to investigate the impact 
of margin in the new optimization framework. The prescription dose, target volume and 
the beam arrangement are shown in Table 4-1.  
Case 
Prescription Dose 
(GyRBE) 
CTV Volume (cc) Beam Angle 
SBT #1 
CTV63 63 86.07 
(270, 0) 
(90, 0) 
(180, 0) 
(60, 275) 
CTV74 74 26.42 
SBT #2 70 36.8 
SBT #3 56 33.7 
H&N #1 
CTV54 54 141.29 
(0,0) 
(160,0) 
(200,0) 
CTV60 60 160.89 
CTV63 63 68.00 
H&N #2 
CTV54 54 108.00 
CTV60 60 127.26 
H&N #3 
CTV54 54 110.38 
CTV60 60 98.94 
CTV63 63 10.23 
Table 4-1: Prescription doses, CTV volumes, and the beam angles (gantry, couch). 
 The nominal dose distribution and robustness against range uncertainties and 
setup uncertainties were both evaluated. The robustness was evaluated by the same 9 
scenarios used for worst-case optimization. The DVH band plot, as well as the worst dose 
metrics occurred among uncertainties scenarios, was used for analysis. In addition to the 
3% range uncertainty, a stress test was performed on the normalized CTV volume covered 
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by the 100% prescription dose for the range estimation error varying from 0.5% to 4.0%, 
with 0.5% interval.  
4.1.3 Results 
 Using an i7 6-core CPU desktop, the time spent on dose calculation, sensitivity 
vector evaluation and optimization of each method are list in Table 4-2. Parallel computing 
toolbox in Matlab was used to accelerate the worst-case dose calculation and sensitivity 
evaluation. The preparation time before optimization for the WC method and the SenR 
method was comparable. During optimization, the SenR method using PTV as target 
volume (SenR-PTV) was as efficient as the Conv method, and it was on average 22 times 
faster than the WC method. And the SenR plans using CTV as target volume (SenR-CTV) 
were faster than the SenR-PTV plans due to fewer voxels to consider during optimization. 
One thing to note is that the computational time comparison is based on the solvers 
developed in our group, and the actual time of voxel-wise worst-case method will be 
different in commercial treatment planning system.  
Case 
Pre-optimization time (s) Optimization runtime (s) 
Nominal 
dose 
calculation 
Worst-case 
dose 
calculation 
Sensitivity 
calculation 
Conv WC 
SenR-
PTV 
SenR-
CTV 
SBT #1 41.8 106.3 129.8 75.5 2296.5 74.1 66.7 
SBT #2 30.0 66.8 55.3 73.1 1070.6 73.4 73.0 
SBT #3 28.2 75.5 44.7 76.0 909.5 75.1 59.9 
H&N #1 210.0 638.1 408.6 129.7 2211.6 129.4 93.8 
H&N #2 208.7 649.2 346.6 114.7 2477.0 105.4 80.9 
H&N #3 174.3 546.6 408.6 121.5 3269.0 133.0 103.4 
Table 4-2: Computational time comparison of the four plans of each patient. 
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4.1.3.1 Nominal dose comparison 
 Figure 4-2 shows the nominal DVHs comparison among the WC plans, SenR-CTV 
plans and SenR-PTV plans for the SBT #1 patient and H&N #2 patient. Several OARs are 
selected for the SBT and H&N sites, respectively, and the differences of their mean and 
maximum doses between the SenR plans and the WC plans are presented in Table 4-3 and 
Table 4-4. Without uncertainties, the Conv, WC, SenR-PTV and SenR-CTV methods achieved 
similar CTV dose coverage.  
 The SenR-CTV plans had better OAR sparing compared with the WC plans. For 
example, in the SBT #1 patient, SenR-CTV reduced the mean dose and max dose of the left 
cochlea by 20.2 GyREB and 18 GyRBE from WC, and the dose sparing of other OARs were 
also improved except the max dose to the right optical nerve. In the H&N #1 patient, the 
doses to the parotids were also lower in SenR-CTV plan compared with the WC plan. The 
average reduction of [Dmean, Dmax] of the SenR-CTV plans from the WC plans were [4.7, 
3.4] GyRBE for the SBT cases and [2.5, 3.3] GyRBE for the H&N cases.  
 The overall OAR sparing of SenR-PTV was comparable with the WC. For example, 
in the three SBT cases, the mean and max brainstem doses were both reduced in SenR-PTV 
relative to WC. SenR-PTV plans also achieved lower Dmax to the left optical nerve and 
chiasm, but the Dmax to the left cochlea in the SBT #2 patient was greater due to an 
overlap with PTV. In the H&N case, a reduction of dose in the brainstem, larynx and spinal 
cord was observed in the SenR-PTV plans. The average reduction of [Dmean, Dmax] of the 
SenR-PTV plans from the WC plans were of [2.0, 1.5] GyRBE for the SBT cases, and [0.8, 0.8] 
GyRBE for the H&N cases. 
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Figure 4-2: Comparison of nominal DVHs for patients SBT #1 and H&N #1 of the WC 
method (solid), SenR-CTV method (dotted), and SenR-PTV method (dashed). 
 
SenR-CTV – WC (GyRBE) SenR-PTV – WC (GyRBE) 
Dmean Dmax Dmean Dmax 
SBT Case #1 #2 #3 #1 #2 #3 #1 #2 #3 #1 #2 #3 
L Opt Nrv -8.4 -4.3 -4.8 -3.5 -2.9 -1.1 -2.3 -5.0 +1.1 -1.5 -2.1 -0.7 
R Opt 
Nrv 
-4.5 -1.0 -9.9 +0.5 -4.2 -2.7 -0.7 -0.7 -2.0 +1.3 -1.0 +2.0 
 
SBT #1 
H&N #1 
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Chiasm -1.2 -8.9 -1.6 0.0 -4.2 -0.3 +2.1 -3.3 +0.5 -0.1 -8.0 -0.9 
Brainste
m 
-6.8 -3.6 -1.3 -1.9 -7.6 -3.7 -6.2 -2.5 -1.2 -2.4 -0.9 -2.7 
L Cochlea -20.2 -3.5 0.0 
-
18.0 
-1.0 0.0 -13.1 +6.2 0.0 -9.0 +11.4 0.0 
R Cochlea -4.4 -0.6 0.0 -9.6 -0.8 0.0 -7.0 -2.0 0.0 -11.2 -1.4 0.0 
Table 4-3: OAR mean dose and max dose reduction of the SenR plans from the WC plans, 
for the SBT cases under nominal situation. A negative sign represents a dose reduction 
from the WC plans. 
 
SenR-CTV – WC (GyRBE) SenR-PTV – WC (GyRBE) 
Dmean Dmax Dmean Dmax 
H&N Case #1 #2 #3 #1 #2 #3 #1 #2 #3 #1 #2 #3 
Brainstem -0.5 -1.1 -0.2 -2.0 -4.8 -2.6 -0.1 -1.2 -0.1 -1.0 -8.3 -1.6 
Constrictors -3.5 -3.2 -2.9 
-
10.6 
-3.1 -1.2 -1.0 +0.5 +3.3 +3.7 +2.4 +3.2 
R 
Submandib
ular Gland 
+3.4 
-
16.0 
+1.2 0.0 -3.7 -1.2 +3.0 -0.6 -10.0 +0.4 -1.2 -1.5 
Larynx -6.3 -1.9 -2.8 
-
11.7 
-4.9 -7.5 -3.4 -0.8 -2.7 -4.0 -1.0 -6.3 
L Parotid -3.8 -9.5 -1.2 -0.5 -2.1 -0.3 -0.8 -2.1 +1.6 -0.7 -1.1 +1.7 
R Parotid -0.8 -0.7 -0.1 -3.1 -0.2 -0.7 +0.2 -0.8 +1.1 +3.4 -1.8 +3.9 
Spinal Cord -1.3 -1.1 -1.3 -3.3 -2.3 -4.3 -1.1 -0.7 -1.3 -1.5 -0.1 -5.4 
Table 4-4: OAR mean dose and max dose reduction of the SenR plans from the WC plans, 
for the H&N cases under nominal situation. A negative sign represents a dose reduction 
from the WC plans. 
4.1.3.2 Robust analysis 
 The DVH bands of CTVs and selected OARs indicating the plan robustness with 
range and setup uncertainties for the SBT #1 and the H&N #2 patients are shown in Figure 
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4-3 and 
 
Figure 4-4, where the solid lines in each plot are the DVHs of the nominal case, and the 
bands bound the worst-case distributions. A narrower band means greater resilience to 
uncertainties. Qualitatively, both the SenR approach and WC method improved the 
robustness of CTVs and OARs from conventional PTV-based method for the two disease 
sites.  
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 With range uncertainties, similar or more compacted CTV bands were observed in 
the SenR-PTV plans compared with the WC plans. The SenR-CTV plans also resulted in 
narrow CTV bands, but there was a slightly larger underdosed region of CTV in these plans. 
The robustness against setup uncertainties was similarly improved by SenR-PTV and SenR-
CTV.  
 In addition to better target volume robustness, a decrease in OAR sensitivity was 
observed in both the SenR-PTV and SenR-CTV plans. For example, the DVH bands of the 
optical nerves and optical chiasm in the SBT #1 patient, and the left parotid in the H&N#2 
patient are narrower than that in Conv.  
 Compared with Conv plans, the lowest D95%, V95% and V100% were improved 
by SenR and WC. Overall SenR-PTV and WC achieved better CTV dose metrics. On average, 
under range uncertainties, the lowest [D95%, V95%, V100%] of CTV were increased from 
[93.8%, 88.5%, 47.4%] in Conv, to [99.3%, 99.5%, 86.6%] in WC, [97.7%, 97.9%, 81. %] in 
SenR-CTV and [98.8%, 99.3%, 85.1%] in SenR-PTV, respectively. Under setup 
uncertainties, the average lowest [D95%, V95%, V100%] of CTV were increased from 
[95.4%, 94.9%, 65.1%] in Conv, to [99.4%, 99.6%, 87.1%] in WC, [97.0%, 97.1%, 77.9%] in 
SenR-CTV and [98.2%, 98.3%, 83.9%] in SenR-PTV, respectively. 
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Figure 4-3:  DVH bands of the SBT #1 patient including 2 range uncertainties (left column) 
and 6 setup uncertainties (right column). The first row is Conv plans, the second row is the 
WC plans, the third row is SenR-CTV plans, and the last row is the SenR-PTV plans. 
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Figure 4-4: DVH bands of the H&N#2 patient including 2 range uncertainties (left column) 
and 6 setup uncertainties (right column). The first row is Conv plans, the second row is the 
WC plans, the third row is SenR-CTV plans, and the last row is the SenR-PTV plans. 
 Figure 4-5 shows the V100% stress test results, where the range estimation error 
increased from 0% to 4%, which is 1.0% outside of the expected worst case. V100% 
degrades with increasing range estimation error but the SenR-PTV method shows slower 
degradation and greater robustness than WC.  
 100 
 
Figure 4-5: The patient-averaged worst V100% of the three methods, when range 
uncertainty varies from 0.0% to 4.0%.  
4.1.3.3 Spot level analysis 
 In order to better understand the mechanism of SenR method, an analysis on the 
scanning spot level is demonstrated using the SBT #1 patient as an example. The spot-level 
dose difference between Conv method and SenR-CTV method when undershooting (+3% 
range uncertainties) happens is shown in Figure 4-6. In this analysis, a point of interest in 
the target, which is inside an underdosing area when undershooting, is found and the 
scanning spots located within 2 cm radius sphere of this cold spot are extracted. These 
scanning spots from four different beam directions are the main contributors to the dose of 
the point of interest. The total dose from these local scanning spots is shown in Figure 
4-6.A, with the first row being the transverse plane and the second row being the sagittal 
plane. From left to right, each column represents the Conv nominal, the Conv 
undershooting, SenR-CTV nominal and SenR-CTV undershooting conditions, respectively. 
The peak position of the dose distribution in the Conv (SenR) nominal plan is marked P1 
(P2), denoted as the crosshairs in the first (last) two columns of images in Figure 4-6. P1 
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and P2 are used as the reference points when comparing the dose change when 
undershooting. For comparison, the isodose display is normalized to the P-point dose of the 
corresponding nominal case without range error. When the range is overestimated, a 20% 
reduction in the P-point dose is observed in the Conv case. However, the high sensitivity 
combination is quantified in the new optimization framework and correctly penalized. As a 
result, to deliver dose to the same point of interest, a different combination of spots is 
selected. When the same undershooting happens, the P-point dose only drops 5% in the 
SenR plan. A closer examination of the scanning spots distribution reveals why the SenR 
optimized combination is more resilient to the range estimation error. Different from the 
Conv approach that chooses spots that match their distal edges, in the SenR approach, 
spots are slightly mismatched. Spots from beam 1 and 4 contribute their proximal edges to 
P and the spot from beam 3 contributes its lateral edge. When the range is over-estimated, 
the slightly undershoot spots from beam 1 and 4 would retract while the contribution from 
beam 3 remains unchanged due to the smooth lateral dose profile. This combination is 
equally resilient to range underestimation due to the same reason that the dose to a given 
point is contributed by a mixture of distal, lateral, and proximal edges. The last two are not 
as sharp as the distal edge thus more resilient to range estimation error.  
 102 
 
Figure 4-6: Spot-level analysis around a cold spot for the SBT #1 patient when range 
undershooting. (A) The total dose from the local scanning spots within 2 cm radius sphere 
of the cold spot. The first row is the transverse plane and the second row is the sagittal 
plane. (B) The dose contribution of the local spots from each beam direction. From left to 
right, each column represents the Conv nominal condition, Conv undershooting condition, 
SenR-CTV nominal condition and SenR-CTV undershooting condition. 
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4.1.4 Discussion 
 Current proton treatment planning methods manage robustness by performing 
optimization on a finite number of hypothetical worst cases. A drawback for the existing 
worst-case method is that it may be too conservative in certain cases, resulting in 
unacceptable dosimetric compromise142 yet is inadequate for extreme case where the error 
exceeds expectation. The uncertainties are sparsely sampled in the worst-case approach, 
which is unprepared for positioning and range errors different from these sparsely-
sampled cases. In comparison, in the SenR framework, robustness is included as a linear 
regularization term that not only softens the impact of robustness consideration, but also 
allows flexible adjustment of the robustness to meet varying requirements. In the nominal 
cases where the uncertainties are low, the dosimetric quality is better preserved. Due to 
the differences, SenR method may particularly benefit cases where the uncertainties are 
difficult to accurately estimate, highly heterogeneous in the same cohort, or variable over 
the treatment course. Since the sensitivity is calculated as a gradient of the spot dose 
distribution, our method does not depend on a specific set of expected positioning or range 
uncertainties, which is needed in the worst-case optimization.  This difference lends the 
flexibility of trading off the robustness with dosimetry by adjusting the sensitivity term 
weighting without needing to estimate the uncertainties explicitly. This new robust 
optimization method is thus different from previous approaches of adjusting the worst case 
weights132, using multi-criteria optimization135, and using the normalized dose interval 
volume constraints143. 
 Another drawback of worst-case methods is that they are computationally 
inefficient due to the time needed to optimize a significantly larger optimization problem 
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for all scenarios. The runtime of the SenR optimization is 22 times shorter than that of the 
voxel-wise worst-case method excluding pre-optimization calculation of the sensitivity 
matrix and worst-case doses, and 8 times shorter including pre-optimization calculation, 
while achieving comparable robustness in the hypothetical worst cases. 
 In this study, the SenR method is implemented on both CTV and PTV. The SenR-
PTV method achieves comparable robustness towards the expected worst cases and OAR 
sparing as the WC method. Sen-CTV attains superior OAR sparing with a slight compromise 
in the CTV robustness while avoiding the substantial degradation seen in the conventional 
PTV plans. The different target volumes offer additional flexibility in clinical practice for 
the trade-off between OAR sparing and CTV coverage robustness. This is also feasible due 
to the demonstrated fast SenR planning speed. As an additional advantage, SenR is versatile 
and independent of the underlying proton dose calculation algorithms, of which, a model-
based method and a Monte Carlo method were used showing consistent results.  
 The proposed method is particularly effective for targets in the heterogeneous 
environment where the sensitivity is captured in the perturbation term. The effectiveness 
of the regularized-sensitivity is highly dependent on the beam and spot arrangement. As 
shown by the spot level analysis, instead of matching the distal edges, SenR tends to 
combine distal, proximal and lateral edges of spots for improved robustness.  Figure 4-6 
shows one such possible robust combinations and the new optimization framework allows 
us to efficiently and globally find these combinations. The importance of combining spots 
for both plan robustness and conformality was discussed by Liu et al49,144. One of the main 
contributions here is to describe the intricate spot interdependence with a new 
mathematical model that can be efficiently solved.  
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 The proposed method applies to scenarios where the same location is covered by 
multiple beams. However, field-matching may happen when different parts of the CTV are 
treated by different beams. The proposed method may result in a mismatch in the 
gradients at the field-matching lines that leads to cold and hot spots with position and 
range uncertainties. Further investigation is needed to understand and mitigate such dose 
heterogeneities. 
4.1.5 Conclusion 
 We developed a novel computationally efficient robust optimization method for 
IMPT. The robustness is calculated as the spot sensitivity to both range and shift 
perturbations. The dose fidelity term is then regularized by the sensitivity term. The new 
SenR method offers the flexibility to balance between the dosimetry and the robustness. In 
the stress test, SenR is shown resilient to greater than expected uncertainties. The SenR 
FMO method is incorporated into the group sparsity based framework for robust BOO in 
the next section. 
4.2 Robust Beam Orientation Optimization for Intensity-
Modulated Proton Therapy38  
4.2.1 Introduction  
 In general, both plan robustness and plan quality/conformality of IMPT depend on 
beam angle selection. An ideal IMPT treatment planning process should include beam angle 
selection and fluence map optimization (FMO) simultaneously. In current clinical practice, 
the proton beam angles are manually selected first by a planner. Different from X-ray 
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therapy where equiangular or arc beams are often acceptable, the proton beam 
orientations are typically asymmetric, and need to be more carefully considered for factors 
such as the water-equivalent thickness to the target, nearby OAR sparing, heterogeneity of 
tissues in the beam path, and setup robustness etc12–14. To minimize low dose regions and 
speed up treatment delivery, there are practically fewer beam angles in a typical proton 
plan, which makes the selection of proton beam angle particularly important. Planners’ 
experience and skill can heavily influence the final treatment plan quality.  For complicated 
patient cases, tedious trial-and-error attempts may be needed to find better beam 
configurations. Yet, human operators cannot effectively search the enormous coplanar and 
non-coplanar beam space, resulting in inconsistent planning results. Beam orientation 
optimization (BOO) using a computational model is, therefore essential for improving IMPT.  
 There have been limited IMPT BOO studies. Cao et al.46 applied a local 
neighborhood search (LNS) algorithm to the IMPT BOO problem and implemented it on 
prostate cancer to improve beam arrangement145. The LNS is confined to be within a small 
search space near the initial condition, which still has to be manually selected. Later Lim et 
al.146 used global search methods, such as branch-and-bound and simulated annealing, to 
find a good feasible solution as the initial condition for LNS, but these stochastic methods 
were only demonstrated on much smaller coplanar IMPT problems. In Chapter 2, we 
developed an integrated BOO and FMO framework for non-coplanar IMPT35. Based on 
group sparsity regularization, this algorithm efficiently performs a global search on non-
coplanar candidate beams and finds a dosimetrically optimal solution. 
 Besides plan dosimetric quality, uncertainty or plan robustness is important for 
IMPT. The proton dose uncertainties sensitive to both patient positioning and range 
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estimation uncertainties8–10,49,127 can lead to severely under-dosed target and over-dosed 
OARs. For IMPT, the commonly worst-case optimization method21-40 improves the plan 
robustness at the cost of substantially increased computational cost10,133. To avoid the 
additional burden of calculating the worst cases and provide the robustness consideration 
as a soft constraint, we modeled the scanning spot sensitivity concerning range and 
positioning uncertainties as a regularization term in the optimization in Section 4.137. We 
showed improved dosimetry, robustness to larger range uncertainties, and an order of 
magnitude faster optimization time than the worst case approach. 
 In the previous IMPT frameworks, robustness and BOO were studied separately, 
despite their obvious inter-dependence. For instance, beams passing through highly 
heterogeneous tissues are likely more sensitive to range and positioning uncertainties than 
beams passing through homogeneous tissues. It may cause more dosimetric compromise to 
achieve robustness for these beams. The robustness consideration complicates beam 
selection in manual IMPT planning, making integrated robust BOO and FMO even more 
urgently needed. Pflugfelder et al127 modeled the interdependence of beam orientation and 
robustness as a lateral tissue heterogeneity across the proton pencil beams. Their 
heterogeneity number, is then used to guide beam angle selection128,129. After evaluating the 
heterogeneity of each beam, Bueno et al128 recommended to change the beam direction if 
the heterogeneity exceeded a threshold, and Toramatsu et al129 proposed to use the beams 
with minimum heterogeneity in single field uniform dose (SFUD) plans. These heuristic 
heterogeneity-guided beam angle selection methods have not quantitatively incoporated 
the robustness consideration in IMPT optimization and potentially dismiss dosimetrically 
superior beam orientations. Cao et al46,145,146 combines the worst-case approach and local 
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neighborhood search algorithm to achieve robust beam angle selection. However, in 
addition to the limitations above being confined to the local search, in each search step, a 
subproblem of worst-case FMO is solved, making the method impractically slow.  
 In this work, we develop a novel unified robust optimization framework for IMPT, 
that integrates robust beam orientation selection and robust fluence map optimization in a 
single problem and then solve this global optimization problem. The BOO is achieved by 
group sparsity regularization, and robustness is promoted by the lateral tissue 
heterogeneity penalty and dose sensitivity regularization.  
4.2.2 Methods  
 The integrated robust BOO and FMO framework is formulated with a dose fidelity 
term, a heterogeneity-weighted group sparsity term, and a dose sensitivity regularization 
term. The details are described as follows. 
4.2.2.1 Heterogeneity-weighted group sparsity 
 The group sparsity-based BOO (GSBOO) framework presented in Equation 2-1 is 
designed to select beams for good dosimetry, and the robustness is not considered yet. In 
order to select beams with less sensitivity to setup uncertainties, we incorporate lateral 
tissue heterogeneity into the current group sparsity term, to encourage the algorithm to 
choose beams with less lateral tissue heterogeneity. The lateral tissue heterogeneity 
observed along beam 𝑏 is quantified by its heterogeneity index  ℎ𝑏 , which is defined as 
follows. 
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 First, as shown in Figure 4-7, a coordinate system is created for each pencil beam 
(scanning spot) in beam 𝑏, with the 𝑧 axis along the central axis of the pencil beam and 
pointing from the source to the patient. The central axis of 𝑖th pencil beam is located at 
(𝑥𝑖, 𝑦𝑖), and the position of (𝑥𝑖, 𝑦𝑖 , 0) is where the pencil beam enters the patient.  
 
Figure 4-7: Diagram showing the coordinates used in the heterogeneity index calculation 
for a specific pencil beam.  
 With discrete sampling, the heterogeneity index of 𝑖th pencil beam in beam 𝑏 at the 
depth 𝑧𝑘, denoted as  ℎ𝑏,𝑖
𝑘 , is defined as: 
ℎ𝑏,𝑖
𝑘 = (
∑ 𝜙𝑖(𝑥𝑗 , 𝑦𝑗 , 𝑧𝑘)𝑗∈𝒮𝑖(𝑧𝑘) ∙ [𝑆rel(𝑥𝑗 , 𝑦𝑗 , 𝑧𝑘) − 𝑆rel(𝑥𝑖, 𝑦𝑖, 𝑧𝑘)]
2
∑ 𝜙𝑖(𝑥𝑗 ,  𝑦𝑗 , 𝑧𝑘)𝑗∈𝒮𝑖(𝑧𝑘)
)
1/2
, 
                                                                       Equation 4-5    
where 𝑆rel(𝑥𝑗 , 𝑦𝑗 , 𝑧𝑘)  is the relative stopping power ratio at the voxel (𝑥𝑗 , 𝑦𝑗 , 𝑧𝑘), and  
𝜙𝑖(𝑥𝑗 ,  𝑦𝑗 , 𝑧𝑘) is the particle fluence at (𝑥𝑗 , 𝑦𝑗 , 𝑧𝑘) for the 𝑖th pencil beam. The sampling set 
of lateral voxels at depth 𝑧𝑘 is written as 𝒮𝑖(𝑧𝑘). In the analytical model, the lateral dose 
distribution of pencil beam 𝑖 is approximated as a single Gaussian distribution, with a 
standard deviation of 𝜎𝑖(𝑧𝑘) at depth 𝑧𝑘. The sampling set 𝒮𝑖(𝑧𝑘) at each depth is selected 
to include the voxels within 3𝜎𝑖(𝑧𝑘) from the central axis. 
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 The depth-specific  ℎ𝑏,𝑖
𝑘  is evaluated and summed up from 𝑧𝑘 = 0…𝑅𝑏,𝑖, which is 
the path spanning from where the pencil beam enters the patient to the end of its range. 
The sum generates a single metric to indicate the lateral heterogeneity affecting the 𝑖th 
pencil beam in beam 𝑏: 
ℎ𝑏,𝑖 =∑ℎ𝑏,𝑖
𝑘
𝑅𝑏,𝑖
𝑘=0
. 
                                                                       Equation 4-6    
 The heterogeneity index values of all scanning spots in the same beam 𝑏 are then 
averaged to represent the beam heterogeneity. Therefore, the heterogeneity index of beam 
𝑏, denoted as ℎ𝑏 , is calculated as: 
ℎ𝑏 = 
1
𝑛𝑏
∑ℎ𝑏,𝑖
𝑛𝑏
𝑖=1
, 
                                                                       Equation 4-7    
where 𝑛𝑏 is the number of scanning spots in beam 𝑏. 
 Then ℎ𝑏 is evaluated for each candidate beam and used to weigh the group sparsity 
in Equation 2-1. The heterogeneity-weighted group sparsity BOO (HBOO) is thus 
formulated as: 
minimize
𝒙
   Γ(𝐴𝒙) +∑𝛼𝑏ℎ𝑏‖𝒙𝑏‖2
1/2
𝑏∈ℬ
   
subject to   𝒙 ≥ 0. 
                                                                       Equation 4-8    
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In this algorithm, the beams with higher lateral heterogeneity are more heavily penalized 
in the group sparsity term, resulting in selecting beams with higher dose fidelity and less 
sensitivity to setup errors. 
4.2.2.2 Robust BOO-FMO 
 Even though the beams more resilient to setup errors are preferred in Equation 
4-8, the range uncertainty has not been considered in FMO. Sensitivity regularization37 is 
thus incorporated into Equation 4-8 to achieve simultaneous robust beam angle selection 
and robust fluence map optimization. The integrated robust BOO and FMO framework is 
written as: 
minimize
𝒙
   Γ(𝐴𝒙) +∑𝛼𝑏ℎ𝑏‖𝒙𝑏‖2
1/2
𝑏∈ℬ
+ ∑ 𝜆𝑘𝒔𝑘
𝑇𝒙
𝑘∈{𝒖,𝒗}
   
subject to   𝒙 ≥ 0, 
                                                                       Equation 4-9    
 This Sensitivity regularization and Heterogeneity weighting based BOO and FMO 
framework (SHBOO-FMO), allows robust beams to be selected and robust fluence map to 
be generated in a single equation.  SHBOO will be used in place of SHBOO-FMO for the rest 
of the section when referring to the BOO algorithm and the selected beams for brevity. 
4.2.2.3 Evaluations 
 This SHBOO-FMO method was tested on two patients with the skull base tumor 
(SBT) and two bilateral head-and-neck (H&N) patients. Four beams were selected for the 
SBT patients and three beams for the H&N patients. For each patient, there were about 700 
to 800 candidate beams. For each candidate beam, dose calculation for the scanning spots 
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covering the CTV and a 5 mm margin was performed by  matRad51,52. In matRad, the lateral 
beam width is calculated as the root sum square of the initial beam width from Safai et al153 
and the lateral broadening from Gottschalk et al154. The CTV was set as the optimization 
target. The prescription dose, target volume, and average spot count per beam for each 
patient are shown in Table 4-5.  
Case 
Prescription Dose 
(GyRBE) 
CTV Volume 
(cc) 
Average Spots per 
Beam 
SBT #1 56 33.7 2537 
SBT #2 70 36.8 2650 
H&N #1 
CTV54 54 108.0 
10077 
CTV60 60 127.3 
H&N #2 
CTV54 54 110.4 
9433 CTV60 60 99.0 
CTV63 63 10.2 
Table 4-5: Prescription doses, CTV volumes and average number of spots per beam for each 
patient. 
 The dosimetry and plan robustness of the proposed SHBOO-FMO method was 
compared against 1) the voxel-wise worst-case FMO method with manually selected beams 
(MAN-WC), and 2) sensitivity-regularized FMO method with the same manual beams 
(MAN-SenR). The voxel-wise worst-case optimization considered nine scenarios, including 
one nominal scenario and the 8 worst-case scenarios same as those in Section 4.1.2.3. 
 In addition to the robustness of the final plan, the sole robustness of the selected 
beams by SHBOO-FMO, was also evaluated and compared with the following beam sets: 1) 
manually selected beams, 2) GSBOO beams selected by Equation 2-1, and 3) HBOO beams 
selected by Equation 4-8. The comparison was performed by creating plans using the same 
conventional CTV-based FMO method (Conv), using the aforementioned beam sets. Same 
candidate beam set, spot population, and dose calculation scheme were used for different 
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BOO algorithms. The acronym used for each method and its definition can be found in 
Table 4-6. 
Acronym Definition 
SHBOO-FMO 
Group sparsity based integrated BOO and FMO framework with 
sensitivity regularization and heterogeneity weighting 
SHBOO 
Short for SHBOO-FMO when referring to the BOO algorithm and the 
beams selected by SHBOO-FMO 
MAN Manually selected beams 
GSBOO Group sparsity based BOO algorithm 
HBOO Heterogeneity-weighted group sparsity BOO algorithm 
Conv Conventional CTV-based FMO method 
MAN-Conv 
GSBOO-Conv 
HBOO-Conv 
SHBOO-Conv 
Conventional CTV-based FMO plan with MAN, GSBOO, HBOO, and 
SHBOO beams, respectively 
MAN-WC 
CTV-based voxel-wise worst-case FMO method with manually selected 
beams 
MAN-SenR Sensitivity-regularized FMO method with manually selected beams 
Table 4-6: Acronym of each method and its definition. 
4.2.3 Results 
4.2.3.1 Runtime and selected beams 
 The dose, sensitivity and heterogeneity calculation for all the candidate beams 
were performed on a Xeon 20-core CPU server operating at 3.10 GHz clock, with Matlab 
and its Parallel Computing Toolbox. The averaged time per beam to calculate the three data 
is listed in Table 4-7. The most time-consuming step during preparation is the evaluation of 
the sensitivity vector. The averaged runtime for GSBOO, HBOO, and SHBOO, on an i7 CPU 
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desktop, is also shown in Table 4-7. Depending on the target size, these BOO process took 
about 6-75 minutes to complete. With the additional heterogeneity weighting and 
sensitivity regularization, the SHBOO method reduced the runtime from the original GSBOO 
method approximately by half. 
Case 
Calculation time per beam (s) BOO runtime (s) 
Dose Sensitivity Heterogeneity GSBOO HBOO SHBOO 
SBT #1 0.4 1.5 1.5 804 745 362 
SBT #2 0.6 2.0 1.6 1102 999 682 
H&N #1 1.9 24.0 8.2 3214 2978 1446 
H&N #2 1.4 14.9 7.2 4407 3996 2728 
Table 4-7: Preparation time and runtime of each BOO method for the tested patients. 
4.2.3.2 Beam robustness 
 The beam robustness was compared among the plans using different BOO methods 
but the same conventional CTV-based approach (Conv) for fluence map optimization.  
 Figure 4-8 shows the DVH bands of the CTVs of these Conv plans with range 
uncertainty and setup uncertainty for the SBT patients and H&N patients. In these DVH 
band plots, the solid lines are the nominal DVHs without uncertainties, the dotted lines and 
bands bound the worst-case dose distributions, and the horizontal and vertical lines label 
the worst D95% of each method for each CTV. For the tested cases, the beam robustness of 
the GSBOO method is not maintained. For example, the GSBOO beams lead to wide DVH 
bands under range uncertainties for the SBT #2 and H&N #2 patients, and wide bands 
under setup uncertainties for the two SBT patients. With heterogeneity-weighted group 
sparsity, the beam robustness against setup uncertainty is improved from the GSBOO 
beams for the four tested patients, while the robustness against range uncertainty varies 
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among patients. With the SHBOO method, the beams with superior range robustness over 
manual beams and HBOO beams are selected while the setup robustness is maintained or 
improved.  
 The D98%, D95%, V95% and V100% of each CTV with range uncertainties and 
setup uncertainties were evaluated and plotted in Figure 4-9. Compared with the manual 
selection, the lowest (worst) D98%, D95%, V95%, and V100% were improved by the 
SHBOO method. On average, the lowest [D98%, D95%, V95%, V100%] of CTV increased 
from [90.9%, 93.9%, 91.1%, 70.6%] in MAN beams, to [96.0%, 98.6%, 98.6%, 96.1%] in 
SHBOO beams. Under setup uncertainties, the average lowest [D98%, D95%, V95%, 
V100%] of CTV increased from [92.1%, 94.8%, 94.3%, 78.9%] in MAN beams, to [93.5%, 
96.6%, 97.0%, 92.0%] in SHBOO beams. 
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Figure 4-8: CTV DVH bands of the four patients, indicating the robustness of the beams 
chosen by different methods. The situation with only range uncertainty is shown on the left 
and situation with only setup uncertainty is shown on the right. The worst D95% of each 
method is labeled by reference lines in the x-y plane. The two CTVs in the H&N #1 patient 
are plotted together in the third row, and the three CTVs in the H&N #2 patient are plotted 
together in the fourth row, with different transparencies. 
 
Range Uncertainty 
H&N #1 
H&N #2 
SBT #1 
SBT #2 
Setup Uncertainty 
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Figure 4-9: The comparison of worst D98% (top row), D95% (second row), V95% (third 
row), and V100% (bottom row) of the CTVs as a percentage of prescription doses, for every 
patient, between the plans with Conv FMO and MAN, GSBOO, HBOO and SHBOO beams, 
respectively. The situation with only range uncertainty is shown on the left and situation 
with only setup uncertainty is shown on the right in each plot. 
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4.2.3.3 Plan robustness 
 The plan robustness of SHBOO-FMO method was compared with the plan with 
manual beams and voxel-wise worst-case FMO (MAN-WC) as well as that with manual 
beams and SenR FMO (MAN-SenR). The CTV DVH bands of the three methods are shown in 
Figure 4-10 for the SBT patients and the H&N patients. Under range uncertainties, 
narrower DVH bands were observed in the SHBOO-FMO plans compared with the MAN-WC 
plans, and the CTV underdosage in the MAN-SenR plans was also improved by the SHBOO-
FMO method. Under setup uncertainties, the SHBOO-FMO method was less robust than 
MAN-WC but comparable with or more robust than MAN-SenR. 
 The lowest (worst) D98%, D95%, V95% and V100% of each CTV with range 
uncertainties and setup uncertainties were also evaluated and plotted in Figure 4-11.  
Compared with MAN-SenR, the D98%, D95%, V95% and V100% were improved by the 
SHBOO-FMO method. On average, the lowest [D98%, D95%, V95%, V100%] of CTV were 
increased from [94.0%, 97.4%, 97.6%, 94.6%] in MAN-SenR plans, to [96.2%, 98.8%, 
98.7%, 96.7%] in SHBOO-FMO plans. Under setup uncertainties, the averaged lowest 
[D98%, D95%, V95%, V100%] of CTV were increased from [93.1%, 96.5%, 96.9%, 92.0%] 
in MAN-SenR plans, to [93.8%, 96.9%, 97.3%, 93.0%] in SHBOO-FMO plans. Overall the 
MAN-WC method achieved the best CTV metrics, with the averaged lowest [D98%, D95%, 
V95%, V100%] of [97.5%, 98.8%, 99.4%, 97.4%] under range uncertainties and [97.9%, 
99.1%, 99.6%, 97.9%] under setup uncertainties. 
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Figure 4-10: CTV DVH bands of the four patients, indicating the robustness of the plans 
generated by SHBOO-FMO, MAN-WC and MAN-SenR. Situation with only range uncertainty 
is shown on the left and situation with only setup uncertainty is shown on the right. The 
two CTVs in the H&N #1 patient are plotted together  in the third row, and the three CTVs 
in the H&N #2 patient are plotted together in two figures in the fourth row. The worst 
D95% of each method is labeled by reference lines in the x-y plane.  
 
Range Uncertainty Setup Uncertainty 
H&N #1 
H&N #2 
SBT #1 
SBT #2 
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Figure 4-11: The comparison of worst D98% (top row), D95% (second row), V95% (third 
row), and V100% (bottom row) of the CTVs as a percentage of prescription doses, for every 
patient, between the MAN-WC plan, MAN-SenR plan and SHBOO-FMO plan Situation with 
only range uncertainty is shown on the left and situation with only setup uncertainty is 
shown on the right. 
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4.2.3.4 Nominal dose comparison 
 Several OARs are selected for the SBT and H&N sites, respectively, and the 
differences of their mean and maximum doses between the SHBOO plans and the MAN 
plans are presented in Table 4-8, and Table 4-9, respectively. Figure 4-12 shows the 
nominal DVHs comparison between the SHBOO-FMO method and MAN-WC method for the 
four tested patients. 
 The SHBOO-FMO plans achieved substantially better OAR sparing compared with 
the MAN-WC plans. For example, in the SBT cases, the dose sparing of all the OARs was 
improved. In the SBT #2 patient, the SHBOO-FMO plan reduced the max dose to the right 
optical nerve and left eye by 13.9 GyRBE and 25.6 GyRBE from the MAN-WC plan. In the 
H&N cases, the overall OAR sparing was also improved by SHBOO-FMO method from MAN-
WC method, except for the increase of mean dose to the right submandibular gland. The 
average reduction of [Dmean, Dmax] of the SHBOO-FMO plans from the MAN-WC plans 
were [6.3, 6.6] GyRBE for the SBT cases and [1.9, 5.1] GyRBE for the H&N cases.  
 From Table 4-8 and Table 4-9, the overall OAR sparing of SHBOO-FMO was better 
than MAN-SenR in the SBT cases and comparable with the MAN-SenR in the H&N cases. 
The average reduction of [Dmean, Dmax] of the SHBOO-FMO plans from the MAN-SenR 
plans were of [2.1, 2.4] GyRBE for the SBT cases, and [-0.4, 2.5] GyRBE for the H&N cases. 
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Figure 4-12: Comparison of nominal DVHs for four patients between the SHBOO-FMO 
method (solid) and MAN-WC method (dotted). 
SBT Case 
SHBOO-FMO – MAN-WC (GyRBE) SHBOO-FMO – MAN-SenR (GyRBE) 
Dmean Dmax Dmean Dmax 
#1 #2 #1 #2 #1 #2 #1 #2 
L Opt Nrv -5.1 -15.1 -1.4 -0.9 +0.1 -10.1 +0.8 +1.4 
R Opt Nrv -13.9 -1.8 -4.6 -11.2 -2.1 -0.2 -2.0 -4.6 
Chiasm -2.4 -13.7 -0.8 -7.2 -2.1 -5.1 +0.2 -4.2 
Brainstem -1.5 -4.6 -5.8 -7.3 -0.4 -0.4 -3.3 2.3 
L Eye -0.6 -13.7 -5.4 -25.6 +0.5 -6.0 -2.2 -16.7 
R Eye -1.2 0.0 -8.4 0.0 -0.1 0.0 -0.7 0.0 
L Cochlea 0.0 -3.6 0.0 0.0 0.0 0.8 0.0 +1.2 
R Cochlea 0.0 -4.9 0.0 -6.7 0.0 -2.1 0.0 -3.5 
Table 4-8: OAR mean dose and max dose reduction of the SHBOO-FMO plans from the 
MAN-WC plans and MAN-SenR, for the SBT cases under nominal situation. 
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H&N Case 
SHBOO-FMO – MAN-WC(GyRBE) 
SHBOO-FMO – MAN-
SenR(GyRBE) 
Dmean Dmax Dmean Dmax 
#1 #2 #1 #2 #1 #2 #1 #2 
R 
Submandibular 
Gland 
-6.8 +11.5 -5.3 -0.3 +9.2 +10.3 -1.6 +0.8 
L Parotid -3.8 -0.4 -1.9 -0.3 +5.7 +0.9 +0.3 0.1 
R Parotid -1.5 -3.3 0.0 -4.3 -0.8 -3.2 +0.2 -4.0 
Larynx -3.2 -2.3 -5.4 -9.6 -1.3 0.0 -0.5 -3.9 
Spinal Cord -1.6 -2.3 -5.9 -8.7 -0.5 -0.3 -3.6 -2.8 
BrainStem -1.8 -0.4 -13.6 -4.1 -0.7 -0.1 -8.8 -0.8 
Oral Cavity +0.1 -3.3 +2.9 -9.2 +1.9 -0.4 +5.5 +1.5 
Constrictors -3.4 -1.2 -6.3 -2.2 -0.2 +1.0 -3.2 0.0 
L Middle Ear -3.4 -5.3 -10.1 -9.1 -1.8 -10.5 -4.8 -16.5 
Esophagus -1.8 -3.4 -6.8 -11.9 -0.8 -1.3 -2.0 -7.7 
Mandible +0.7 -4.9 0.2 -0.1 +4.0 -3.5 +3.0 -6.0 
Table 4-9: OAR mean dose and max dose reduction of the SHBOO-FMO plans from the 
MAN-WC plans and MAN-SenR, for the H&N cases under the nominal situation. 
4.2.4 Discussion 
 To the best of our knowledge, this work describes the first integrated IMPT 
optimization method that optimizes beam orientation and scanning-spot intensities for 
both nominal dose conformality and robustness. In clinical IMPT planning, it is known that 
the beam orientation directly impacts the IMPT dose conformality and robustness, 
requiring substantial manual effort from the dosimetrists to find better beam angles. 
However, a manual search is ineffective in identifying beams from the enormous non-
coplanar space for both dosimetry and robustness goals. The combination of group sparsity, 
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lateral heterogeneity, and sensitivity into a formulation that allows global search on all 
feasible candidate beams is a major contribution of this study.  
 Proton beam has a unique feature that protons stop at the end of its Bragg Peak. 
This is different from the photon beam. As a result, the experience in beam angle selection 
is different from the photon experience, in particular for non-coplanar beams. The results 
on tested patients show that the proposed robust BOO algorithm selects beams that are 
more resilient to range and setup uncertainties. The final SHBOO-FMO plans better spared 
the OAR sparing compared with the voxel-wise worst-case method on the manual beams 
while maintaining similar robustness. Compared with the plans using manually selected 
beams and SenR FMO, the proposed method achieved better target coverage under 
simulated uncertainties. 
 Furthermore, the sensitivity regularization term helps to directly generate the 
fluence map which is more robust to range and setup uncertainties. In the limited existing 
IMPT BOO studies, the FMO is a nested subproblem that is solved post-hoc, which not only 
is inefficient but also compromises plan optimality as the FMO results could influence the 
selected beams. Our algorithm integrates FMO and BOO in a single function to ensure that 
both the beam orientations and the spot intensities are matched for the desired dosimetry 
and robustness. The second important aspect of our study is that rather than the commonly 
used worst-case scenario optimization method for FMO, we apply sensitivity regularization 
to improve the plan robustness against errors. This non-scenario-based method can be 
easily and efficiently incorporated into the optimization framework and provides the 
flexibility between the dosimetry and the robustness. Our previous study37 showed that the 
sensitivity regularization is more effective to mitigate range uncertainties than setup 
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uncertainties. The latter weakness is largely remedied in the current framework by 
incorporating lateral tissue heterogeneity in the BOO. 
 Compared with GSBOO35 or SenR37 alone, the planning time of SHBOO-FMO is 
longer. The computational cost of the proposed method attributes to two main components: 
the pre-optimization calculation and optimization of the objective function. 
Preoptimization includes calculating a dose calculation matrix, heterogeneity index, and 
sensitivity vector for each candidate beam. Under the analytical calculation model, the dose 
calculation and heterogeneity evaluation, in theory, could have shared the same ray tracing 
step to reduce the calculation time shown in Table III. Calculation of the sensitivity is more 
time-consuming. However, this parallel calculation process can be accelerated using the 
modern graphics processing unit (GPU) platform. Further acceleration is expected using a 
non-uniform sampling of the dose matrix to have a higher resolution in the CTV and its 
vicinity and lower resolution elsewhere. 
 For the optimization step, the Equation 4-9 itself is a large-scale problem due to 
the extra freedom of proton energy in IMPT and a large number of non-coplanar candidate 
beams used in this study. With the linear formulation of the sensitivity regularization term 
and the proximal operators derived in Section 235, we are able to efficiently solve the 
problem with FISTA, which converges at a rate of  𝑂(1 𝑘2⁄ ) amongst the first-order 
methods56. Moreover, by adding the sensitivity regularization term, the time spent on beam 
pruning within the SHBOO method is reduced to approximately half of the initial group-
sparsity based BOO method.  
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 It is necessary to clarify that the study only handles range uncertainties and setup 
errors from interfractional setup variations. Other sources of uncertainties such as 
intrafractional respiratory motion and anatomy changes, which heavily affect the beam 
selection process, require separate approaches to tackle. Biological effect is another 
important factor to consider in BOO. In our future work, linear energy transfer (LET) will 
be included in this framework to encourage selecting beams with a higher biological effect 
on the target and lower biological risk on the OARs. 
4.2.5 Conclusion 
 We developed a novel IMPT robust optimization method, which efficiently solved 
robust BOO and FMO in a unified framework, generating plans with superior dosimetry and 
good robustness. 
 
 
 127 
5  APPENDIX 
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THE FISTA ALGORITHM 
 The Fast Iterative Shrinkage-Thresholding Algorithm (FISTA)56, an accelerated 
proximal gradient algorithm, has been successfully utilized to solve all of the problems 
presented in this dissertation. In this appendix, the format of the optimization problem 
required for this algorithm, and line-search procedure, will be described. 
5.1 Optimization Problem Formulation 
The FISTA algorithm solves problems in the following canonical form 
𝑚𝑖𝑛𝑖𝑚𝑖𝑧𝑒 𝑓(𝒙) + 𝑔(𝒙), 
Equation 5-1 
where 𝑓 is a smooth convex function, which is continuously differentiable with Lipschitz 
continuous gradient (∇𝑓); 𝑔 is a function which is possibly nonsmooth, but has a proximal 
operator that can be evaluated efficiently. The proximal operator with step size 𝑡 > 0 for 
function 𝑔 is defined by 
prox𝑡𝑔(𝒙) = argmin
𝒚
  𝑔(𝒚) +
1
2𝑡
‖𝒚 − 𝒙‖2
2. 
Equation 5-2 
To solve an optimization problem with FISTA, the optimization must be rewritten to fit this 
canonical form. All problems in this dissertation can easily be expressed in this canonical 
form.  
5.2 The Line-Search Algorithm 
The implementation of line-search FISTA algorithm is shown below. 
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FISTA with line-search  
Initialize  𝒙𝟎: =  𝟎, 𝒗𝟎: = 𝒙𝟎 , 𝒕𝟎 > 𝟎 ,𝟎 < 𝒓 < 𝟏 
for  𝒌 = 𝟏, 𝟐,… , 𝒏,   do 
            𝒕 ≔ 𝒕𝒌−𝟏/𝒓  
            Repeat 
                  𝜽 ≔ {
 𝟏                                                                                 𝐢𝐟   𝒌 = 𝟏 
𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐫𝐨𝐨𝐭 𝐨𝐟 𝒕𝒌−𝟏𝜽
𝟐 = 𝒕𝜽𝒌−𝟏
𝟐 (𝟏 − 𝜽)         𝐢𝐟   𝒌 > 𝟏
 
                  𝒚 ≔ (𝟏 − 𝜽)𝒙𝒌−𝟏 + 𝜽𝒗𝒌−𝟏 
                  𝒙 ≔ 𝐩𝐫𝐨𝐱𝒕𝒈(𝒚 − 𝒕𝜵𝒇(𝒚)) 
              break if   𝒇(𝒙) ≤ 𝒇(𝒚)+< 𝜵𝒇(𝒚), 𝒙 − 𝒚 > +
𝟏
𝟐𝒕
‖𝒙 − 𝒚‖𝟐
𝟐 
              𝒕 ≔ 𝒓𝒕 
        𝒕𝒌 ≔ 𝒕 
        𝜽𝒌 ≔ 𝜽 
        𝒙𝒌 ≔ 𝒙 
        𝒗𝒌 ≔ 𝒙𝒌 +
𝟏
𝜽𝒌
(𝒙𝒌 − 𝒙𝒌−𝟏) 
end 
return 𝒙 
Table 5-1: Pseudo code for FISTA with line search. 
5.3 Solving Group Sparsity based BOO Problem 
The group sparsity based problems are re-written to fit the canonical form in Equation 5-1. 
The process of re-writing Equation 2-1 is shown in this section as an example.  Solving the 
rest of group-sparsity based problems follows the similar rule. The objective function in 
Equation 2-1 can be re-written in the following format 
𝑓(𝒙) =   Γ(𝐴𝒙), 
𝑔(𝒙) = ∑𝛼𝑏‖𝒙𝑏‖2
𝑝
𝑏∈𝐵
+ 𝐼≥0(𝒙), 
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Equation 5-3 
where 𝐼≥0(𝒙) is an indicator function, defined as 
𝐼≥0(𝒙) = {
0          if 𝒙 ≥ 0
∞       otherwise
 
Equation 5-4 
The gradient of  𝑓(𝒙) is calculated as 
∇𝑓(𝒙) = 𝐴T∇Γ(𝐴𝒙) 
Equation 5-5 
After obtaining the gradient of the function 𝑓, the next step is to derive a formula for the 
proximal operator of the function 𝑔. In the BOO problem, 𝑔(𝒙) is a separable sum: 𝑔(𝒙) =
∑ 𝑔𝑏(𝒙𝑏)
𝐵
𝑏=1 , where 
𝑔𝑏(𝒙𝑏) = ∑𝛼𝑏‖𝒙𝑏‖2
𝑝
𝑏∈𝐵
+ 𝐼≥0(𝒙𝑏) 
Equation 5-6 
It follows from the separable sum rule for proximal operators that the problem evaluating 
the proximal operator of  𝑔(𝒙) reduces to independently evaluating the proximal operators 
of the functions 𝑔𝑏(𝒙𝒃). To simplify notation, we derive an expression for the proximal 
operator of the function ℎ(𝒙) = 𝛼‖𝒙‖2
𝑝 + 𝐼≥0(𝒙). Evaluating the proximal operator of ℎ 
requires solving the optimization problem: 
minimize
𝒙
 𝛼‖𝒙‖2
𝑝 +
1
2𝑡
‖?̂? − 𝒙‖2
2  
subject to 𝒙 ≥ 0 
Equation 5-7 
The proximal operator of function ℎ is: 
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prox𝑡ℎ(𝒙) = prox𝛼𝑡‖∙‖2
𝑝(max (𝒙, 0)) 
Equation 5-8 
There is a known form of proximal operator for both L2,1-norm and L2,1/2-norm155:  
prox𝑡‖∙‖2(𝒙) =  𝒙 − 𝒙 ∙ min (
𝑡
‖𝒙‖2
, 1) 
prox
𝑡 ‖∙‖2
1
2
(𝒙) =
{
 
 
 
 0,                                                                       if 𝑡‖𝒙‖2
−1.5 >
2√6
9
𝒙√
2
√3
sin (
1
3
(arccos (
3√3
4
𝑡‖𝒙‖2
−1.5) +
𝜋
2
)) ,   otherwise
 
Equation 5-9 
By deriving the gradient of function 𝑓 and proximal operator of function 𝑔, the Equation 
2-1 is then readily solved using FISTA.  
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